<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006545</article-id><article-id pub-id-type="pmc">PMC11859743</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics17020178</article-id><article-id pub-id-type="publisher-id">pharmaceutics-17-00178</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Lipid Nanoparticles Carrying Essential Oils for Multiple Applications as Antimicrobials</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>da Silva</surname><given-names>Elenice Francisco</given-names></name><xref rid="af1-pharmaceutics-17-00178" ref-type="aff">1</xref><xref rid="c1-pharmaceutics-17-00178" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>dos Santos</surname><given-names>Fernanda Aparecida Longato</given-names></name><xref rid="af2-pharmaceutics-17-00178" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Pires</surname><given-names>Henrique Machado</given-names></name><xref rid="af3-pharmaceutics-17-00178" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Bastos</surname><given-names>Luciana Machado</given-names></name><xref rid="af1-pharmaceutics-17-00178" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6097-5449</contrib-id><name><surname>Ribeiro</surname><given-names>L&#x000ed;gia Nunes de Morais</given-names></name><xref rid="af1-pharmaceutics-17-00178" ref-type="aff">1</xref><xref rid="c1-pharmaceutics-17-00178" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Vassallo</surname><given-names>Antonio</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Bergonzi</surname><given-names>Maria Camilla</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-17-00178"><label>1</label>Institute of Biotechnology, Federal University of Uberlandia, Uberlandia 38405-302, Brazil; <email>lucianabastos.ufu@gmail.com</email></aff><aff id="af2-pharmaceutics-17-00178"><label>2</label>School of Veterinary Medicine, Federal University of Uberlandia, Uberlandia 38402-018, Brazil; <email>fernanda.longato60@gmail.com</email></aff><aff id="af3-pharmaceutics-17-00178"><label>3</label>Vaccine Development Laboratory, Butantan Institute, S&#x000e3;o Paulo 05503-900, Brazil; <email>henrique.pires.esib@esib.butantan.gov.br</email></aff><author-notes><corresp id="c1-pharmaceutics-17-00178"><label>*</label>Correspondence: <email>elenice.silva@ufu.br</email> (E.F.d.S.); <email>nuneslica@gmail.com</email> (L.N.d.M.R.)</corresp></author-notes><pub-date pub-type="epub"><day>31</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>178</elocation-id><history><date date-type="received"><day>13</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>24</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>29</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Lipid nanoparticles (LNPs) are versatile delivery systems with high interest because they allow the release of hydrophobic and hydrophilic molecules, such as essential oils (EOs) and plant extracts. This review covers published works between 2019 and 2024 that have reported the use of essential EO-based LNPs with antimicrobial properties and applications in human and animal health, as well as biopesticides. In the human healthcare field, reports have addressed the effect of encapsulating EOs in lipid nanosystems with antiviral, antibacterial, antiprotozoal and antifungal activities. In animal care, this still needs to be more deeply explored while looking for more sustainable alternatives against different types of parasites that affect animal health. Overall, the antibacterial activities of LNPs carrying EOs are described as alternatives to the use of synthetic antibiotics. In the field of agriculture, studies showed that these approaches in the control of phytopathogens and other pests that affect food production. There is a growing demand for innovative and more sustainable technologies. However, there are still some challenges to be overcome in order to allow these innovations to reach the market.</p></abstract><kwd-group><kwd>lipid nanoparticles</kwd><kwd>essential oil</kwd><kwd>antimicrobial activity</kwd></kwd-group><funding-group><award-group><funding-source>Project CNPq/MCTI/CT-Health N&#x000b0; 52/2022&#x02014;Actions in Science, Technology and Innovation to Face Antimicrobial Resistance</funding-source><award-id>408640/2022-7</award-id></award-group><funding-statement>This research was funded by Project CNPq/MCTI/CT-Health N&#x000b0; 52/2022&#x02014;Actions in Science, Technology and Innovation to Face Antimicrobial Resistance (408640/2022-7).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-17-00178"><title>1. Introduction</title><p>Nanotechnology is an innovative field with many applications in the pharmaceutical, cosmetic, food and agricultural industries [<xref rid="B1-pharmaceutics-17-00178" ref-type="bibr">1</xref>]. The nanoencapsulation of active agents is one of its most successful applications, which is designed to improve their functional performance and increase the stability and bioactivity due to a sustained bioactive release profile [<xref rid="B2-pharmaceutics-17-00178" ref-type="bibr">2</xref>]. In the farming field, it has gained relevance in pesticides, nanofertilizers and nanoremediation. It produces several benefits, such as a reduction in the agrochemical concentration in formulations and water contamination, improvement of crop development and soil quality, and decrease in occupational risks [<xref rid="B3-pharmaceutics-17-00178" ref-type="bibr">3</xref>]. Undoubtedly, nanotechnology is consolidated in the biomedicine field. It represents a paradigm shift in healthcare strategies. The industry, clinicians, patients, regulatory authorities and governments have to be prepared to explore such novel technologies as efficient and safe treatments and theranostics in order to improve the life quality of humans and other animals [<xref rid="B4-pharmaceutics-17-00178" ref-type="bibr">4</xref>].</p><p>In particular, lipid nanoparticles (LNPs) are emerging as promising alternatives for active molecule delivery systems development, mainly due to their biocompatibility and ability to encapsulate hydrophobic and hydrophilic molecules, in addition to enabling the use of biodegradable and cheap excipients [<xref rid="B2-pharmaceutics-17-00178" ref-type="bibr">2</xref>,<xref rid="B5-pharmaceutics-17-00178" ref-type="bibr">5</xref>,<xref rid="B6-pharmaceutics-17-00178" ref-type="bibr">6</xref>].</p><p>However, there are several translational challenges to be overcome before nanomedicines can be marketed. Thus, considering the multidisciplinary expertise of the university, industry and clinical-based researchers, the DELIVER framework (D&#x02014;defined target product profile; E&#x02014;essential characterization; L&#x02014;lead candidate optimized; I&#x02014;intellectual property patented; V&#x02014;validated efficacy and safety; E&#x02014;economical and scalable; R&#x02014;regulatory and clinical pathway) was recently proposed [<xref rid="B4-pharmaceutics-17-00178" ref-type="bibr">4</xref>]. This framework comprises a set of criteria that must be considered during the early stage of nanodrug development. It can help to enable the clinical success, regulatory approval and market registration of nanodrugs in the near future. This report also suggests the use of biocompatible and biodegradable nanomaterials, merging the desired efficacy with biocompatibility, stability and manufacturability [<xref rid="B4-pharmaceutics-17-00178" ref-type="bibr">4</xref>]. Furthermore, specifically regarding agricultural ecosystems, it is essential to explore the use of biodegradable and ecofriendly nanomaterials that promote plant growth and metabolism, minimizing the environmental risks [<xref rid="B3-pharmaceutics-17-00178" ref-type="bibr">3</xref>].</p><p>In this sense, the nanoencapsulation of bioactive compounds (e.g., EO) has garnered huge interest in nanomedicine and agrochemical development, while also considering the sustainability and low-cost production issues [<xref rid="B2-pharmaceutics-17-00178" ref-type="bibr">2</xref>,<xref rid="B7-pharmaceutics-17-00178" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceutics-17-00178" ref-type="bibr">8</xref>]. In the last few years, many strategies have been explored in terms of LNP, polymer-based nanocapsule/nanoparticle and cyclodextrin developments [<xref rid="B6-pharmaceutics-17-00178" ref-type="bibr">6</xref>]. In here, we focus the discussion on lipid-based nanosystems, such as nanoemulsions (NE), liposomes (LUV), niosomes (NIO), solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC).</p><p>LUV were the first lipid-based nanoformulations developed. They are spherical micro or nanovesicles consisting of one or more phospholipid bilayers surrounded by an internal aqueous compartment, which enables the encapsulation of hydrophobic, hydrophilic and amphiphilic molecules [<xref rid="B9-pharmaceutics-17-00178" ref-type="bibr">9</xref>,<xref rid="B10-pharmaceutics-17-00178" ref-type="bibr">10</xref>]. In addition, cholesterol is commonly added to the formulations to decrease the fluidity of unsaturated fatty acids, increasing the permeability of hydrophobic drugs [<xref rid="B11-pharmaceutics-17-00178" ref-type="bibr">11</xref>]. There are several preparation methods, with lipid film hydration being the most used [<xref rid="B12-pharmaceutics-17-00178" ref-type="bibr">12</xref>]. LUV are biocompatible and non-immunogenic. However, the high-cost production and the limited physicochemical stability usually restrict their applications [<xref rid="B1-pharmaceutics-17-00178" ref-type="bibr">1</xref>,<xref rid="B5-pharmaceutics-17-00178" ref-type="bibr">5</xref>,<xref rid="B13-pharmaceutics-17-00178" ref-type="bibr">13</xref>].</p><p>NIO are comparable with LUV in terms of their structural organization in mono- or multilayer spherical vesicles composed of amphiphilic molecules, showing particle sizes in the range of 10&#x02013;1000 nm [<xref rid="B14-pharmaceutics-17-00178" ref-type="bibr">14</xref>]. On the other hand, NIO are based on non-ionic surfactants, and cholesterol and can encapsulate hydrophilic and hydrophobic molecules in its structure [<xref rid="B15-pharmaceutics-17-00178" ref-type="bibr">15</xref>]. In comparison with LUV, NIO are more physiochemically stable, offering benefits such as low-cost production and a higher shelf life [<xref rid="B16-pharmaceutics-17-00178" ref-type="bibr">16</xref>]. There are several well-determined NIO preparation methods, including thin-film hydration, ether injection, reverse-phase evaporation, microfluidization, supercritical carbon dioxide fluid, transmembrane pH gradient, multiple membrane extrusion, heating and bubble techniques [<xref rid="B14-pharmaceutics-17-00178" ref-type="bibr">14</xref>,<xref rid="B15-pharmaceutics-17-00178" ref-type="bibr">15</xref>].</p><p>NE are nanostructured colloids composed of water and oil and stabilized by a surfactant and cosurfactant [<xref rid="B17-pharmaceutics-17-00178" ref-type="bibr">17</xref>]. This nanosystem is kinetically stable and the particle sizes typically range from 20 to 200&#x02009;nm [<xref rid="B9-pharmaceutics-17-00178" ref-type="bibr">9</xref>,<xref rid="B18-pharmaceutics-17-00178" ref-type="bibr">18</xref>]. NE have some advantages compared with other colloidal systems, such as a simple and low-cost preparation process and physical and thermodynamic stability [<xref rid="B5-pharmaceutics-17-00178" ref-type="bibr">5</xref>]. The most used techniques to produce NE can be categorized into high-energy (high-pressure homogenization, microfluidization and ultrasonication) and low-energy (phase inversion/composition and emulsification) methods [<xref rid="B18-pharmaceutics-17-00178" ref-type="bibr">18</xref>].</p><p>SLN are considered the first lipid nanoparticles generation and were reported for the first time in 1990. They have emerged as a promising alternative to LUV in order to overcome their previously mentioned disadvantages. In general, SLN are composed of individual or a mixture of solid lipids at room and body temperatures, plus an aqueous phase containing a surfactant [<xref rid="B13-pharmaceutics-17-00178" ref-type="bibr">13</xref>]. Different types of lipids can be used, such as triglycerides (trimyristin, tripalmitin), fatty acids (stearic acid, oleic acid) and waxes (cetyl palmitate, beeswax). Its lipid content represents approximately 0.1&#x02013;30 (%, <italic toggle="yes">w</italic>/<italic toggle="yes">w</italic>), while the surfactants are generally used in concentrations of 0.5&#x02013;5% [<xref rid="B13-pharmaceutics-17-00178" ref-type="bibr">13</xref>]. On the other hand, NLC are the second lipid nanoparticles generation and are based on a lipid structural matrix composed of a mixture of solid and liquid lipids at both body and room temperatures, stabilized by a surfactant [<xref rid="B19-pharmaceutics-17-00178" ref-type="bibr">19</xref>]. They were developed in order to solve some limitations of SLN, such as the low capacity for loading molecules and the expulsion of the active compound during the storage period. NLC have a higher capacity to encapsulate hydrophobic molecules compared with SLN due to the imperfect crystalline structure of the lipid matrix. In addition, it offers high drug stability, excellent bioavailability, safety, a low production cost and scale-up ability [<xref rid="B20-pharmaceutics-17-00178" ref-type="bibr">20</xref>,<xref rid="B21-pharmaceutics-17-00178" ref-type="bibr">21</xref>,<xref rid="B22-pharmaceutics-17-00178" ref-type="bibr">22</xref>]. The most common production methods for SLN and NLC include high-pressure homogenization (hot and cold), microemulsification, solvent emulsification (evaporation or diffusion), solvent injection, double emulsion, ultra-sonication or high-speed homogenization, spray drying and microfluidics techniques [<xref rid="B23-pharmaceutics-17-00178" ref-type="bibr">23</xref>].</p><p>Lipid-based nanosystems can provide a flexible platform for dermal and transdermal drug delivery and vaccine developments [<xref rid="B9-pharmaceutics-17-00178" ref-type="bibr">9</xref>,<xref rid="B24-pharmaceutics-17-00178" ref-type="bibr">24</xref>], such as Spikevax<sup>&#x000ae;</sup> and Comirnaty<sup>&#x000ae;</sup> indicated for COVID-19 immunization [<xref rid="B25-pharmaceutics-17-00178" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceutics-17-00178" ref-type="bibr">26</xref>]. Moreover, the specific structure of LNP provides a safe and stable structure to carry mRNA and other vaccine components [<xref rid="B27-pharmaceutics-17-00178" ref-type="bibr">27</xref>]. The liposomal and LNP systems are among the main technologies used in the development of drugs recently approved by the Food and Drug Administration (FDA) [<xref rid="B25-pharmaceutics-17-00178" ref-type="bibr">25</xref>], in addition to synthetic molecules [<xref rid="B7-pharmaceutics-17-00178" ref-type="bibr">7</xref>].</p><p>In this sense, essential oils (EO) are natural sources of therapeutic molecules. EO come from the secondary metabolism of plants and can be extracted from different structures: bark, leaves, flowers, buds, seeds, roots and fruits. They are complex mixtures of bioactive compounds derived from aromatic plants and are primarily composed of volatile terpenes and terpenoids [<xref rid="B28-pharmaceutics-17-00178" ref-type="bibr">28</xref>]. Several biological properties have been described, including antimicrobial, antioxidant, analgesic, anti-inflammatory, anti-cancer and neuropharmacological effects, as well as repellant, larvicidal and biopesticidal effects [<xref rid="B6-pharmaceutics-17-00178" ref-type="bibr">6</xref>,<xref rid="B28-pharmaceutics-17-00178" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceutics-17-00178" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceutics-17-00178" ref-type="bibr">30</xref>,<xref rid="B31-pharmaceutics-17-00178" ref-type="bibr">31</xref>]. In addition, they are Generally Recognized as Safe (GRAS) by the FDA and the Environmental Protection Agency (EPA), offering low risk to the environment, animals and humans, making them applicable in the medicine, agriculture, food industry and cosmetics fields [<xref rid="B12-pharmaceutics-17-00178" ref-type="bibr">12</xref>,<xref rid="B18-pharmaceutics-17-00178" ref-type="bibr">18</xref>]. However, there are some properties that limit their industrial application such as toxicity, low solubility and physicochemical stability, and high volatility and hydrolysis capacity [<xref rid="B2-pharmaceutics-17-00178" ref-type="bibr">2</xref>]. In order to overcome such limitations, the nanoencapsulation of EO by LNP is considered a versatile alternative. Several systems have been successfully developed for multipurpose uses [<xref rid="B19-pharmaceutics-17-00178" ref-type="bibr">19</xref>,<xref rid="B22-pharmaceutics-17-00178" ref-type="bibr">22</xref>,<xref rid="B32-pharmaceutics-17-00178" ref-type="bibr">32</xref>,<xref rid="B33-pharmaceutics-17-00178" ref-type="bibr">33</xref>,<xref rid="B34-pharmaceutics-17-00178" ref-type="bibr">34</xref>,<xref rid="B35-pharmaceutics-17-00178" ref-type="bibr">35</xref>].</p><p>This review provides an overview of lipid-based nanosystems encapsulating EO with human, veterinary and environmental applications. The applied methodology focused on the selection of works published between 2019 and 2024 that provide data regarding the structural characterization of nanoparticles, physicochemical stability, safety and efficacy assays against microorganisms with interest in the human, veterinary and environmental fields. </p></sec><sec id="sec2-pharmaceutics-17-00178"><title>2. Application of Lipid Nanoparticles Loading Essential Oils as Antimicrobial Agents</title><p>LNP are considered the pioneers in nanostructured drug delivery systems. They were the most reported nanoparticles in clinical trials from 2016 to 2021. LUV were the most described, with 44% of the cases. Since 2016, LUV were the second most approved drug by the FDA (22%), followed by other types of lipid-based formulations (21%) [<xref rid="B25-pharmaceutics-17-00178" ref-type="bibr">25</xref>].</p><p>In 1995, two liposomal drugs were approved by the FDA, Doxil<sup>&#x000ae;</sup> and Abelcet<sup>&#x000ae;</sup>, for the treatments of cancer and fungal infections, respectively. Their clinical success contributed to the approval of several new liposomal drugs, mainly as treatments of infections (AmBisome<sup>&#x000ae;</sup>, ArikayceTM), cancer (DaunoXome<sup>&#x000ae;</sup>, Myocet<sup>&#x000ae;</sup>, Mepact<sup>&#x000ae;</sup>, Vyxeos<sup>&#x000ae;</sup>), respiratory distress syndrome in premature infants (Curosurf<sup>&#x000ae;</sup>) and rare genetic diseases (Onpattro<sup>&#x000ae;</sup>), as well as pain management (DepoDur<sup>&#x000ae;</sup>, Exparel<sup>&#x000ae;</sup>) [<xref rid="B26-pharmaceutics-17-00178" ref-type="bibr">26</xref>,<xref rid="B36-pharmaceutics-17-00178" ref-type="bibr">36</xref>].</p><p>Unfortunately, the emerging antimicrobial drug resistance and the lack of approved antimicrobials have been a public health issue worldwide [<xref rid="B37-pharmaceutics-17-00178" ref-type="bibr">37</xref>]. On the other hand, EO exhibit intrinsic antimicrobial activity, being widely proposed as a viable alternative to solve this problem [<xref rid="B38-pharmaceutics-17-00178" ref-type="bibr">38</xref>]. Furthermore, nanotechnology represents a powerful tool for developing new therapeutic strategies to reach different targets efficiently [<xref rid="B4-pharmaceutics-17-00178" ref-type="bibr">4</xref>]. In this sense, LNP are excellent strategies for EO nanoencapsulation [<xref rid="B39-pharmaceutics-17-00178" ref-type="bibr">39</xref>], being interesting alternatives to enhancing human health by improving the bioavailability and intrinsic antimicrobial properties of EO [<xref rid="B40-pharmaceutics-17-00178" ref-type="bibr">40</xref>,<xref rid="B41-pharmaceutics-17-00178" ref-type="bibr">41</xref>,<xref rid="B42-pharmaceutics-17-00178" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceutics-17-00178" ref-type="bibr">43</xref>,<xref rid="B44-pharmaceutics-17-00178" ref-type="bibr">44</xref>,<xref rid="B45-pharmaceutics-17-00178" ref-type="bibr">45</xref>], as well as their anticancer [<xref rid="B7-pharmaceutics-17-00178" ref-type="bibr">7</xref>,<xref rid="B20-pharmaceutics-17-00178" ref-type="bibr">20</xref>,<xref rid="B28-pharmaceutics-17-00178" ref-type="bibr">28</xref>,<xref rid="B46-pharmaceutics-17-00178" ref-type="bibr">46</xref>,<xref rid="B47-pharmaceutics-17-00178" ref-type="bibr">47</xref>,<xref rid="B48-pharmaceutics-17-00178" ref-type="bibr">48</xref>], hypolipidemic [<xref rid="B49-pharmaceutics-17-00178" ref-type="bibr">49</xref>], antioxidant [<xref rid="B50-pharmaceutics-17-00178" ref-type="bibr">50</xref>], antidiabetic [<xref rid="B51-pharmaceutics-17-00178" ref-type="bibr">51</xref>], anti-inflammatory and analgesic properties [<xref rid="B52-pharmaceutics-17-00178" ref-type="bibr">52</xref>,<xref rid="B53-pharmaceutics-17-00178" ref-type="bibr">53</xref>]. They will exhibit additional relevance once they have biodegradable, biocompatible and ecofriendly properties [<xref rid="B5-pharmaceutics-17-00178" ref-type="bibr">5</xref>].</p><sec id="sec2dot1-pharmaceutics-17-00178"><title>2.1. Applications to Human Health</title><p>Overall, the optimized antimicrobial activity of EO-loaded LNP has been widely described. Exciting results for the treatment of some neglected diseases caused by parasites have been reported. Santos et al. developed chitosan-coated NLCs for <italic toggle="yes">Citrus sinensis</italic> EO delivery against leishmaniasis [<xref rid="B54-pharmaceutics-17-00178" ref-type="bibr">54</xref>]. Hybrid NLC were composed of a mixture of beeswax and <italic toggle="yes">Citrus sinensis</italic> EO or R-limonene (ratio of 70:30), with concentrations of lipid, surfactant (poloxamer 188) and chitosan of 7, 7 and 0.05%, respectively. The particle sizes ranged from 97.9 to 111.3 nm, and the formulation showed stability for 90 days (25 and 4 &#x000b0;C), which enabled a significant reduction in the viability of promastigote forms of <italic toggle="yes">Leishmania amazonensis</italic> when compared with the free active compounds. Ghanbariasad et al. also investigated the leishmanicidal effect of EO-based lipid formulations [<xref rid="B55-pharmaceutics-17-00178" ref-type="bibr">55</xref>]. However, they prepared NE composed of <italic toggle="yes">Cinnamomum zeylanicum</italic> EO (0.5%, <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>) and Tween<sup>&#x000ae;</sup> 20. The nanoparticle size was around 28.0 &#x000b1; 4.0 nm and demonstrated physicochemical stability for 6 months when stored at both 4 and 25 &#x000b0;C. After the NE-loading <italic toggle="yes">Cinnamomum zeylanicum</italic> EO treatment, a total reduction in the viability of <italic toggle="yes">L. major</italic> and <italic toggle="yes">L. tropica</italic> promastigotes (~0%) was observed. Moghadam et al. developed optimized NIO formulations that contained <italic toggle="yes">Bunium persicum</italic> EO against the <italic toggle="yes">Trichomonas vaginalis</italic> parasite [<xref rid="B41-pharmaceutics-17-00178" ref-type="bibr">41</xref>]. This nanosystem was prepared by the thin-layer hydration method using surfactants, cholesterol, distearoyl phosphoethanolamine-polyethylene glycol and <italic toggle="yes">Bunium persicum</italic> EO (1 mg/mL). The encapsulation efficiency (%EE) and particle size were 63.11% and 159.7 nm, respectively, with a suitable stability for 120 days. They observed low nanotoxicity in healthy cells, a higher toxicity in the parasite, and a sustained release profile of the <italic toggle="yes">Bunium persicum</italic> EO at the same temperature and acidity as the <italic toggle="yes">T. vaginalis</italic> microenvironment. Siyadatpanah et al. prepared liposomal systems that contained <italic toggle="yes">Bunium persicum</italic> and <italic toggle="yes">Trachyspermum ammi</italic> EO. The physicochemical properties and in vitro activity against <italic toggle="yes">T. vaginalis</italic> were evaluated [<xref rid="B56-pharmaceutics-17-00178" ref-type="bibr">56</xref>]. LUV were prepared with phosphatidylcholine and cholesterol using the thin-film evaporation method. The size and zeta potential values of the LUV that contained <italic toggle="yes">B. persicum</italic> were 121.0 nm and &#x02212;16.7 mV, respectively, whereas for the <italic toggle="yes">T. ammi</italic> EO, such values were 111.0 nm and &#x02212;9.0 mV, respectively. The %EE of the loaded EO were 51.64 &#x000b1; 1.24% (<italic toggle="yes">B. persicum</italic> EO) and 40.12 &#x000b1; 2.71% (<italic toggle="yes">T. ammi</italic> EO). An EO sustained release profile from liposomal systems for 24 h was reported. In addition, a satisfactory parasite growth inhibition when compared with controls was described, demonstrating its potential as a treatment for this type of infection. These findings strongly indicate that EO-based LNP have potential for the treatment of infectious diseases, such as leishmaniasis and trichomoniasis, demonstrating the importance of EO nanoencapsulation, which improves the chemical stability; bioavailability; and, consequently, therapeutic efficacy.</p><p>There are many reports of EO nanosystems with activity against bacterial species. Fahimnia and coworkers developed a topical nanohybrid gel that contained lavender EO loaded with SLN and demonstrated in vitro antibacterial activity against <italic toggle="yes">Staphylococcus aureus</italic> [<xref rid="B40-pharmaceutics-17-00178" ref-type="bibr">40</xref>]. Tween<sup>&#x000ae;</sup> 80 was employed as the surfactant, lecithin and cholesterol were used as the lipids, and Carbomer 940 was used as the gelling agent. The lavender-EO-based SLN revealed a particle size of 19.24 nm, a PDI of 0.079 and an %EE of 75.46%. It potentiated the antibacterial properties of pure EO due to its sustained release profile, where this property was maintained in the topical gel formulation. Wen et al. developed optimized NLC in gel with activity against <italic toggle="yes">Pseudomonas aeruginosa</italic> [<xref rid="B57-pharmaceutics-17-00178" ref-type="bibr">57</xref>]. They investigated their topical effect in wound infection. This nanosystem was composed of Labrafac&#x02122; lipophilic WL 1349, stearic acid, cinnamon EO (167 mg), Tween<sup>&#x000ae;</sup> 80 and water, with Poloxamer 407 used as the gelling agent. The EO release test exhibited an initial burst release followed by a sustained release profile. The in vitro and in vivo antimicrobial activities were evaluated by the determination of the minimal inhibitory concentration (MIC) and burnt wound model using male Sprague Dawley rats, respectively. They observed that NLC-based cinnamon EO in gel exhibited significant inhibitory activity against a <italic toggle="yes">P. aeruginosa</italic> strain compared with an NLC-based cinnamon EO formulation and pure cinnamon EO. Furthermore, the treatment with nanohybrid NLC successfully healed wounds in rats in 6 days. In other work, the LUV loading of citral (50 mg/mL) inhibited the proliferation of the <italic toggle="yes">Streptococcus mutans</italic> cariogenic species. The LUV were composed of Lipoid S75 and <italic toggle="yes">Citrus limon</italic> var. <italic toggle="yes">pompia</italic> EO or pure citral [<xref rid="B58-pharmaceutics-17-00178" ref-type="bibr">58</xref>]. The EO and citral-based LUV exhibited particle sizes that were around 110.0 nm in both cases. The values of the zeta potential were negative, around &#x02212;85.0 mV (EO-based LUV) and &#x02212;72.0 mV (citral-based LUV). All the formulations were stable throughout 90 days of storage at 25 &#x000b0;C and demonstrated biocompatibility with epithelial cells, which increased the skin repair rate. However, regarding the antibacterial activity, only citral-loaded LUV provided an inhibition of <italic toggle="yes">S. mutans</italic> proliferation. As suggested by the authors, this formulation could be considered suitable for the development of an effective, safe and pleasant mouthwash for the prophylaxis of oral cavities. Overall, these reports validated the use of EO-based LNP as potential antibacterial agents, improving their bioactivity and shelf time.</p><p>LNP can also be applied as a viral infection treatment. Zhang et al. prepared <italic toggle="yes">Artemisia argyi</italic> EO-loaded NLC, investigating its therapeutic effect against the Hepatitis B virus (HBV) in an animal model [<xref rid="B42-pharmaceutics-17-00178" ref-type="bibr">42</xref>]. The formulation was composed of a mixture of glycerin monostearate with caprylic acid/capric triglyceride, EO (0.1 g), poloxamer 188 and egg yolk lecithin. Such a system showed a particle size of 72.33 &#x000b1; 1.58 nm, with a PDI of 0.27 and an %EE of 87.49%. The in vivo results show that this nanosystem exhibited a desirable inhibitory effect on the replication HBV DNA of both the serum and liver of ducks, being a potential antiviral agent for the treatment of HBV infection. There is also a report of a hybrid LUV system in gel composed of imiquimod, <italic toggle="yes">Thymus vulgaris</italic> EO and <italic toggle="yes">Oreganum vulgare</italic> EO and functionalized by a DNA aptamer. This system was designed to treat intraepithelial lesions caused by the human papillomavirus (HPV) [<xref rid="B59-pharmaceutics-17-00178" ref-type="bibr">59</xref>]. The <italic toggle="yes">T. vulgaris</italic> EO (0.25%, <italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>) and <italic toggle="yes">O. vulgare</italic> EO (1%, <italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>) were emulsified by Tween<sup>&#x000ae;</sup> 80. LUV were produced by the ethanol injection method, using cholesterol, phosphatidylcholine, imiquimod, milli-Q water and EO. Moreover, potassium sorbate, hydroxypropylmethylcellulose and propylene glycol were used as excipients to obtain the gel formulation. The LUV were characterized using Dynamic Light Scattering (DLS), which showed appropriate particle sizes (50.0&#x02013;200.0 nm) and PDI values &#x02264; 0.3. The formulations exhibited cytotoxicity in cancer cells without affecting the healthy cells. The results demonstrated that the presence of EO potentiated the imiquimod&#x02013;LUV in vitro efficacy, while the functionalization increased the selectivity for cervical cancer cells.</p><p>EO or their components have also demonstrated an antifungal property [<xref rid="B60-pharmaceutics-17-00178" ref-type="bibr">60</xref>,<xref rid="B61-pharmaceutics-17-00178" ref-type="bibr">61</xref>]. Encapsulation in LNP has been explored, with the aim to develop alternative treatments in the face of increasing multidrug resistance. El-Salam et al. developed hybrid liposomal formulations that encapsulated tea tree EO coated by chitosan [<xref rid="B62-pharmaceutics-17-00178" ref-type="bibr">62</xref>]. The antifungal activity against <italic toggle="yes">Aspergillus flavus</italic>, <italic toggle="yes">Aspergillus fumigatus</italic>, <italic toggle="yes">Microsporum gypsum</italic> and <italic toggle="yes">Fusarium oxysporum</italic> were analyzed through in vitro and in vivo infection models. The hybrid LUV showed a spherical shape, with particles sizes in the range of 360.0&#x02013;420.0 nm, a monodisperse size distribution (PDI = 0.05) and a zeta potential value of +2.6 mV. The in vitro results demonstrated that these nanosystems show fungicidal activity against the analyzed strains at safe concentrations (&#x02264;5 mg/mL), confirming the in vivo biocompatibility and efficacy. An in vivo study on Wister rats revealed that LUV formulations destroyed the fungal cells inside without causing any toxicity to the tissues. Alteriis et al. encapsulated <italic toggle="yes">Lavandula angustifolia</italic> EO in LUV and evaluated its activity against <italic toggle="yes">Candida auris</italic> biofilms [<xref rid="B63-pharmaceutics-17-00178" ref-type="bibr">63</xref>]. The mean particle size was 177.2 &#x000b1; 11.5 nm, with PDI &#x0003c; 0.3 and a zeta potential around &#x02212;3.73 mV. The nanosystem was composed of L-&#x003b1;-phosphatidylcholine, cholesterol and <italic toggle="yes">L. angustifolia</italic> EO (concentration of 10% <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>), and showed in vitro antifungal and antibiofilm properties against <italic toggle="yes">C. auris</italic>. Baldim et al. evaluated the effect of <italic toggle="yes">Lippia sidoides</italic> EO encapsulation in NLC and their potential efficacy against the <italic toggle="yes">C. auris</italic> multidrug-resistant pathogen [<xref rid="B64-pharmaceutics-17-00178" ref-type="bibr">64</xref>]. NLC formulations were prepared through the hot emulsification method, followed by sonication. The formulations were based on oleic acid and Compritol<sup>&#x000ae;</sup> 888, or a combination of carnauba wax and beeswax, and stabilized by sodium dodecyl sulfate. They observed that the lipid matrix composition of NLC affected both the particle size and PDI. At lower surfactant concentrations (1.4 and 2.4% <italic toggle="yes">w</italic>/<italic toggle="yes">w</italic>), the nanocarriers composed of beeswax and carnauba wax presented smaller (301.5 to 318.7 nm) and more homogeneous (PDI 0.19 to 0.22) particles compared with those composed of Compritol<sup>&#x000ae;</sup> 888 (particles sizes between 321.3 to 445.5 nm and PDI 0.33 to 0.41). However, when a higher concentration of surfactant (4.2%; <italic toggle="yes">w</italic>/<italic toggle="yes">w</italic>) was used, it provided smaller particles (213.1 nm) than the other formulations. In relation to the antifungal efficacy, the NLC demonstrated potent activity against <italic toggle="yes">C. auris</italic> with any toxicity in a <italic toggle="yes">Galleria mellonella</italic> in vivo model. Husein et al. investigated the use of EO (eucalyptus and orange) as a liquid lipid in an NLC preparation [<xref rid="B65-pharmaceutics-17-00178" ref-type="bibr">65</xref>]. They tested the antifungal activity against <italic toggle="yes">Candida albicans</italic> strains. The formulations were composed of Miglyol<sup>&#x000ae;</sup> 812 and eucalyptus (35% <italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>) or orange EO (40% <italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>), Kolliphor<sup>&#x000ae;</sup>, distilled water, NaCl and soybean lecithin. Both formulations displayed excellent stability properties over 6 months when stored at 4 &#x000b1; 1 &#x000b0;C, with particle sizes of 163.1 &#x000b1; 10.8 for the NLC-based eucalyptus EO and 144.3 &#x000b1; 1.9 for the NLC-based orange EO. The results indicated that the EO encapsulation into NLC significantly enhanced their antifungal effects. So, these works confirmed the viability of LNP loaded with EO against drug-resistant fungi acting as potential therapeutic strategies.</p><p>Considering the antimicrobial and antibiofilm properties of EO and the previously reported success of their encapsulation in LNP, a complementary approach was explored for the preparation of sanitizers for healthcare applications. Gross et al. developed novel sanitizer tablets that contained clove-EO-loaded NE [<xref rid="B66-pharmaceutics-17-00178" ref-type="bibr">66</xref>]. These tablets presented antimicrobial and acaricide activities, and were prepared by the wet granulation of spray-dried soap. A blend of nonylphenol ethoxylate and coconut fatty acid diethanolamide surfactants, water and clove EO (concentration of 12.5%) was employed. The structural characterization revealed a particle size of 100.0 nm, PDI of 0.3 and zeta potential of &#x02212;19.5 mV. Then, such formulations were incorporated into soap solid matrices. These new systems presented a particle size close to 221.0 nm, PDI of 0.5 and zeta potential of &#x02212;17.2 mV. Antimicrobial activity assays were carried out against Gram-negative (<italic toggle="yes">Escherichia coli</italic>) and Gram-positive (<italic toggle="yes">Staphylococcus aureus</italic>) bacterial strains and yeast (<italic toggle="yes">Candida krusei</italic>). The acaricidal and larvicidal activities were analyzed against ticks (<italic toggle="yes">Rhipicephalus microplus</italic>). The results demonstrated the efficacy of the sanitizer tablet against bacteria, fungi, mites and larvae. Such systems can be used both in healthcare for effective surface disinfection and in animal livestock to control pests that affect animal health. Drais et al. developed a hybrid NE gel skin sanitizer and evaluated the antibacterial activity against <italic toggle="yes">Staphylococcus aureus</italic> and <italic toggle="yes">Escherichia coli</italic> [<xref rid="B67-pharmaceutics-17-00178" ref-type="bibr">67</xref>]. The formulations were composed of peppermint and myrtle EO (10% <italic toggle="yes">w</italic>/<italic toggle="yes">w</italic>; in a 1:1 ratio), Tween<sup>&#x000ae;</sup> 80 and propylene glycol, using carbomer 940 as the gelling agent. The mean particle size, PDI and zeta potential values ranged from 25.83 to 55.86 nm, 0.26 to 0.38 and &#x02212;12.6 to &#x02212;19.6 mV, respectively. In vitro antimicrobial activities against <italic toggle="yes">S. aureus</italic> and <italic toggle="yes">E. coli</italic> were presented. The authors claimed the nanosystems as alternatives in the process of cleansing the skin against these microorganisms. Mechmechani et al. reported that the encapsulation of functional enzymes combined with EO acted as a promising anti-biofilm active that was able to be applied in the food and medical fields [<xref rid="B68-pharmaceutics-17-00178" ref-type="bibr">68</xref>]. Considering these reports and the constant trend toward green biotechnology, there are several insights to be explored in the development of antiseptic/disinfectant nanoformulations.</p><p>These results support the fact that EO nanoencapsulation by different LNP can be innovative therapeutic agents for the treatment of infections caused by viruses, parasites, bacteria and fungi. Their application as sanitizers is also an interesting alternative to be explored more. Furthermore, many studies validated the use of LNP as potential nanosystems for the delivery of lipophilic active molecules, improving the physicochemical stability and reducing their volatility and toxicity [<xref rid="B5-pharmaceutics-17-00178" ref-type="bibr">5</xref>].</p></sec><sec id="sec2dot2-pharmaceutics-17-00178"><title>2.2. Applications in Veterinary Medicine</title><p>The application of nanotechnology is valuable in a wide range of fields of knowledge, including in animal health. The benefits of encapsulating antimicrobial agents as a viable alternative to the use of antibiotics have already been discussed [<xref rid="B69-pharmaceutics-17-00178" ref-type="bibr">69</xref>]. Such uses extend to the area of nutrition. Once it can improve animal digestion, it is able to increase the absorption of nutrients, resulting in a higher quality of products intended for human feeding, such as meat, milk and eggs [<xref rid="B70-pharmaceutics-17-00178" ref-type="bibr">70</xref>,<xref rid="B71-pharmaceutics-17-00178" ref-type="bibr">71</xref>]. In fact, LNP application is still limited in animal production and the prevention and treatment of diseases [<xref rid="B69-pharmaceutics-17-00178" ref-type="bibr">69</xref>]. Moreover, LNP should be applied to all groups of animals, from companion to farming animals, which is clarified throughout this review.</p><p>Broilers were investigated in order to achieve a high performance in feed conversion to ensure rapid growth. However, they are easily affected by bacterial diseases caused by failures in their immune system. Meligy et al. encapsulated oregano (150 mg), cinnamon (200 mg) and clove (50 mg) EO by LUV. Then, they were added to the animal diet to understand their antioxidant and antimicrobial properties, as well as the changes in the intestinal microbiota of broilers from 1 to 38 days [<xref rid="B72-pharmaceutics-17-00178" ref-type="bibr">72</xref>]. A decrease in intestinal bacterial species, such as <italic toggle="yes">Clostridium</italic>, <italic toggle="yes">Escherichia</italic> and <italic toggle="yes">Enterobacteriaceae</italic>, were observed when supplementation (300 and 400 mg/kg) with LUV occurred, as quantified by real-time PCR. Pires et al. developed different NLC formulations that contained several EO (geranium, lemongrass, clove, cinnamon and oregano) [<xref rid="B19-pharmaceutics-17-00178" ref-type="bibr">19</xref>]. These NLC showed in vitro antimicrobial activity against <italic toggle="yes">Campylobacter</italic> isolated from chicken carcasses, with lemongrass, cinnamon and geranium EO being the best bioactives. The NLC showed sizes of 151.8&#x02013;179.2 nm, 245.4&#x02013;231.8 nm and 208.4&#x02013;219.7 nm, respectively; PDI values from 0.13 to 0.23; and zeta potentials around &#x02212;28.8 to &#x02212;40.0 mV. All the systems were stable for 210 days.</p><p>The market for pets has exponentially grown over the years, where the constant searching for higher longevity and quality of life means looking for more efficient and convenient therapies. In this sense, NLC loaded with clove EO (19.75%) and &#x003b1;-mangostin (0.25%) were developed as bioactives, with Span 80 (2&#x02013;4%) as the surfactant, with the aim to control canine periodontitis since low bioavailability is currently observed with the commercially available forms. Satisfactory results were observed in the penetration tests in gingival tissues. The three-dimensional confocal light scanning microscopy indicated that the nanostructured compound resulted in better penetration into the gingival epithelium, being also able to inhibit the growth of <italic toggle="yes">E. coli</italic>, <italic toggle="yes">Salmonella</italic> spp. and <italic toggle="yes">Klebsiella pneumoniae</italic> isolated from the oral cavities of dogs. The NLC had a particle size less than 200.0 nm, PDI values between 0.1 and 0.2 and a zeta potential up to &#x02212;30 mV. The formulations were stable for 60 days when stored at room temperature [<xref rid="B33-pharmaceutics-17-00178" ref-type="bibr">33</xref>]. This field should be more widely explored.</p><p>The development of NE based on tea tree EO with antifungal activity against the <italic toggle="yes">Pythium insidosum</italic>, which causes pythiosis, which affects humans and other animals (mainly horses), was reported. NE with 1% <italic toggle="yes">M. alternifolia</italic> EO showed sizes smaller than 200 nm, a PDI below 0.25 and a negative zeta potential. NE-based EO presented the highest capacity to inhibit <italic toggle="yes">Pythium insidosum</italic> (around 90%) in vitro [<xref rid="B73-pharmaceutics-17-00178" ref-type="bibr">73</xref>].</p><p>The use of nanotechnology in livestock farming can be diverse, including in diagnosis, therapeutics, vaccines, nutraceuticals and thermal insulation [<xref rid="B74-pharmaceutics-17-00178" ref-type="bibr">74</xref>]. Unfortunately, the applications of LNP loaded with EO with antimicrobial, antifungal and antiparasitic activity for veterinary clinical uses are still scarce. Nevertheless, the abovementioned reports make it clear that such innovations demonstrated robust evidence in the development of biodegradable and easily scalable nanoproducts based on green chemistry.</p></sec><sec id="sec2dot3-pharmaceutics-17-00178"><title>2.3. Applications as Biopesticides/Biorepellents</title><p>The global agricultural sector faces major challenges due to plant/animal diseases caused by pests, such as bacteria, fungi and insects. In this context, plant-based nanopesticides have emerged as promising solutions that incorporate substances on the nanometric scale. LNP in particular stand out for their ability to release active compounds in a sustained manner, which increase their efficacy and decrease their toxicity [<xref rid="B75-pharmaceutics-17-00178" ref-type="bibr">75</xref>].</p><p>Pesticides are chemical compounds that are derived from natural or synthetic sources and are designed to control pests and insects [<xref rid="B76-pharmaceutics-17-00178" ref-type="bibr">76</xref>]. On the other hand, repellents are products that prevent diseases transmitted by mosquitoes and ticks, as well as repel or mitigate mosquitoes and pests [<xref rid="B77-pharmaceutics-17-00178" ref-type="bibr">77</xref>].</p><p>There are a range of diseases that disturb the productivity of farm animals and severely affect meat production. Urban pests have also posed threats to human health and well-being. Chemical pesticides remain the most used active for prevention [<xref rid="B78-pharmaceutics-17-00178" ref-type="bibr">78</xref>]. However, these chemicals are often associated with undesirable environmental impacts, such as soil and groundwater contamination, and causing toxic effects on other organisms, such as pollinators [<xref rid="B79-pharmaceutics-17-00178" ref-type="bibr">79</xref>]. Thus, LNP have emerged as alternative nanosystems for pest management. LNP associated with EO have been employed in several approaches, including as larvicidal/adulticidal [<xref rid="B8-pharmaceutics-17-00178" ref-type="bibr">8</xref>,<xref rid="B80-pharmaceutics-17-00178" ref-type="bibr">80</xref>,<xref rid="B81-pharmaceutics-17-00178" ref-type="bibr">81</xref>], acaricidal [<xref rid="B82-pharmaceutics-17-00178" ref-type="bibr">82</xref>], insecticidal [<xref rid="B34-pharmaceutics-17-00178" ref-type="bibr">34</xref>,<xref rid="B83-pharmaceutics-17-00178" ref-type="bibr">83</xref>] and antimicrobial [<xref rid="B19-pharmaceutics-17-00178" ref-type="bibr">19</xref>].</p><p>Overall, some works demonstrated that LNP encapsulating EO exhibit excellent pesticidal activity. Radwan et al. developed NLC based on stearic acid, green tea and fennel EOs [<xref rid="B8-pharmaceutics-17-00178" ref-type="bibr">8</xref>]. The NLC had particle sizes between 277.0 and 287.0 nm, PDI values below 0.1 and zeta potential values between &#x02212;28.22 and &#x02212;34.31 mV. They showed larvicidal and adulticidal activities against <italic toggle="yes">Cullex pipiens</italic>. Hikal et al. formulated NE using oleic acid, sodium glycocholate, and polysorbate 20 honeysuckle or patchouli EO delivery. These NE were tested against the larvae and adults of <italic toggle="yes">Culex pipiens</italic>, where they showed particle sizes around 183.9&#x02013;250.2 nm, PDI values in the range from 0.285 to 0.420 and zeta potentials of &#x02212;49.8 and &#x02212;23.5 mV. The data revealed that the honeysuckle-EO-based NE and patchouli-EO-based NE were more effective than the respective pure EO against <italic toggle="yes">C. pipiens</italic> larvae and adults [<xref rid="B80-pharmaceutics-17-00178" ref-type="bibr">80</xref>].</p><p>Rodrigues et al. developed and characterized NE that contained <italic toggle="yes">Ayapana triplinervis</italic> EO to test the larvicidal activity against <italic toggle="yes">Aedes aegypti</italic> larvae, the vector of the Dengue virus [<xref rid="B81-pharmaceutics-17-00178" ref-type="bibr">81</xref>]. These nanosystems showed the expected activity, with particle size averages between 88.3 and 99.5 nm, PDI values below 0.2 and zeta potentials ranging from &#x02212;17.7 to &#x02212;32.8 mV. Dunan et al. described EO-based NE and evaluated their entomotoxicity and phytotoxicity properties against <italic toggle="yes">Bemisia tabaci</italic>, which affects tomatoes [<xref rid="B84-pharmaceutics-17-00178" ref-type="bibr">84</xref>]. The NE were composed of Tween<sup>&#x000ae;</sup> 80, ethanol, and artemisia EO or rosemary EO (1%). The structural characterization was carried out for freshly prepared formulations and no long-term stability study was carried out. Particle sizes of 217.0 and 199.0 nm, PDIs of 0.36 and 0.42, and zeta potentials of &#x02212;18.63 and 12.27 mV were obtained for the NE prepared with the rosemary EO and artemisia EO, respectively. The entomotoxic and phytotoxic bioassays were performed in climatic chambers by fumigation. An artemisia-EO-based NE and rosemary-EO-based NE resulted in <italic toggle="yes">B. tabaci</italic> mortalities of 60% and 98%, respectively, being the most efficient tested treatments. In terms of phytotoxicity, the highest index was found by a rosemary-EO-based NE. Furthermore, Manjesh et al. reported on NE based on <italic toggle="yes">Pogostemon cablin</italic> EO (obtained from leaves) using a biosurfactant (saponin). Its insecticidal efficacy was investigated against <italic toggle="yes">Tetranychus urticae</italic> adults and <italic toggle="yes">Spodoptera litura</italic> larvae [<xref rid="B85-pharmaceutics-17-00178" ref-type="bibr">85</xref>]. The stability of the prepared NE was measured at room temperature and under an accelerated storage condition (54 &#x000b1; 1 &#x000b0;C) for 14 days. The particle sizes ranged from 46.2 to 71.7 nm with PDIs of 0.49 to 0.69 and zeta potentials of &#x02212;22.62 to &#x02212;29.21 mV. The NE displayed the highest efficacy against <italic toggle="yes">T. urticae</italic>, where they exhibited considerable antifeedant action against <italic toggle="yes">S. litura</italic> larvae.</p><p>Mites are also pests that hinder animal welfare. Hoda et al. developed and tested the toxicity of NE composed of polyethylene glycol, Tween<sup>&#x000ae;</sup> 80, and <italic toggle="yes">Artemisia herba-alba</italic> or <italic toggle="yes">Melia azedarach</italic> EO [<xref rid="B82-pharmaceutics-17-00178" ref-type="bibr">82</xref>]. Transmission electron microscopy analysis revealed particle sizes of 52&#x02013;91.0 nm for the NE loaded with the <italic toggle="yes">M. azedarach</italic> EO and 62&#x02013;69.0 nm for those loaded with the <italic toggle="yes">A. herba-alba</italic> EO. Both formulations showed in vivo acaricidal activity against <italic toggle="yes">H. dromedarii</italic>. Teng et al. proposed NE against the house dust mite <italic toggle="yes">Dermatophagoides farinae</italic> through fumigant, repellent and larvicidal assays. An 80% mortality rate of larvae treated with NE was observed, and thus, they acted as an excellent larvicide. When compared with the pure EO, the NE showed suitable acaricidal activity after 48 h of treatment, but poor fumigant effects against adult <italic toggle="yes">D. farinae</italic> at 12 and 24 h. The EO-based NE repellent effect against <italic toggle="yes">D. farinae</italic> was found to be stable over time [<xref rid="B86-pharmaceutics-17-00178" ref-type="bibr">86</xref>]. Barbhuiya et al. developed NIO loaded with an <italic toggle="yes">Azadirachta indica</italic> EO and evaluated the in vitro antimicrobial activity against two pathogens that affect the plants <italic toggle="yes">Xanthomonas</italic> and <italic toggle="yes">Pantoea</italic>. These systems were composed of neem EO, Tween<sup>&#x000ae;</sup> 80 and soy lecithin. The nanoformulation showed a particle size of 93.3 nm, and when under refrigeration between 4 and 8 &#x000b0;C, showed an increase in size after 30 days of storage. There was a significant increase in the antimicrobial inhibition growth against both bacteria, with 10&#x02009;mg/mL of neem-EO-loaded NIO [<xref rid="B87-pharmaceutics-17-00178" ref-type="bibr">87</xref>]. Adamu et al. reported a ginger-EO-based NE and evaluated its potential to manage the bacterial disease of rice caused by <italic toggle="yes">Xanthomonas oryzae</italic>. The NE was composed of Tween<sup>&#x000ae;</sup> 20 and ginger EO, and it showed a particle size of 73.0 &#x000b1; 0.8 nm, zeta potential of &#x02212;43.2 mV and PDI of 0.21. The antimicrobial activity of the developed nanoformulation was evaluated by the disk diffusion test and a glasshouse trial experiment. The NE efficacy assay showed a concentration-dependent profile, where 125 &#x003bc;L/mL was the most effective concentration in the control, as well as bacterium growth reduction and disease severity index suppression in rice. In addition, the treatment with a ginger-EO-based NE had no phytotoxicity effects, where it displayed the best performance in the reproductive, grain filling and ripening stages, and improved the rice yield [<xref rid="B88-pharmaceutics-17-00178" ref-type="bibr">88</xref>].</p><p>Other insect species are also targets for urban and agricultural control. Palermo et al. proposed some nanosystems against <italic toggle="yes">Tribolium confusum.</italic> They used several EO that were loaded by NE and nanogels. All formulations showed particle sizes between 95.0 and 144.3 nm and PDI values from 0.14 to 0.25. The in vitro repellent activity and acute toxicity assays were carried out by cold aerosol assays. The best nanoformulation was based on anise EO due to its low toxicity [<xref rid="B83-pharmaceutics-17-00178" ref-type="bibr">83</xref>]. M&#x000fa;nera-Echeverri et al. developed NLC loaded by thyme and rosemary EO for the targeting of common pests, such as <italic toggle="yes">M. persicae</italic>, <italic toggle="yes">T. urticae</italic> and <italic toggle="yes">F. occidentalis</italic>, which affect ornamental flowers. The compositions of these NLC included carnauba wax, Tween<sup>&#x000ae;</sup> 80 and Mygliol, and EO as liquid lipids. It was observed that the NLC production method affected the physicochemical parameters. The high shear homogenization method was selected as the best technique to prepare the NLC. The thyme EO-NLC and rosemary EO-NLC had particle sizes of 347.8 and 288.1 nm, a PDI of 0.18 (both cases), zeta potentials of &#x02212;33.8 and &#x02212;34.0 mV, and %EE of 71.9 and 80.6%, respectively. The assessment of contact toxicity on leaf disks showed that the NLC that carried the thyme EO reached mortality rates between 24 and 38% against <italic toggle="yes">F. occidentalis</italic>, and thus, demonstrated moderate insecticidal activity. On the other hand, a rosemary-EO-based NLC showed efficacy against all the pests [<xref rid="B34-pharmaceutics-17-00178" ref-type="bibr">34</xref>]. Tortorici et al. described NLC loaded with rosemary, lavender or peppermint EO. They were tested against <italic toggle="yes">Aphis gossypii</italic>, <italic toggle="yes">Spodoptera littoralis</italic> and <italic toggle="yes">Tuta absoluta</italic>. The formulations were prepared using Softisan<sup>&#x000ae;</sup> 100 as a solid lipid and a surfactant mixture composed of Kolliphor<sup>&#x000ae;</sup> RH40 and Labrafil<sup>&#x000ae;</sup>, and loading the EO with a concentration of 10% <italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>. The results demonstrated a stable colloidal formulation characterized by a homogeneous particle distribution (mean particle size &#x0003c;200.0&#x02009;nm and PDI &#x0003c; 0.3), with a high amount of EO encapsulated (&#x02265;70%). The rosemary-EO-based NLC was the most promising system since it exhibited excellent stability. All the NLC were able to induce a high mortality and reduce the <italic toggle="yes">A. gossypii</italic> progeny significantly by topical contact exposure. However, the lavender- and rosemary-EO-based NLC were able to decrease the feeding activity of <italic toggle="yes">S. littoralis</italic> [<xref rid="B89-pharmaceutics-17-00178" ref-type="bibr">89</xref>].</p><p>It is clear that the application of nanobiotechnology processing EO as nanoformulations constitutes a broad field of research that allows for different approaches to control urban and agricultural pests while reducing the environmental and human health impacts. <xref rid="pharmaceutics-17-00178-t001" ref-type="table">Table 1</xref> summarizes the available data with applications in the human, veterinary and environmental fields.</p></sec></sec><sec id="sec3-pharmaceutics-17-00178"><title>3. The Role of LNPs in Industrial Development</title><p>The industrial potential of LNP-based pharmaceutical products has been increasingly recognized. It has been stimulated by the urgency of novel efficient and safe drugs against microbials. However, the approval of LNP is still a challenge, particularly regarding the scalability, sterilization and regulatory compliance [<xref rid="B14-pharmaceutics-17-00178" ref-type="bibr">14</xref>,<xref rid="B101-pharmaceutics-17-00178" ref-type="bibr">101</xref>,<xref rid="B102-pharmaceutics-17-00178" ref-type="bibr">102</xref>]. Overcoming these challenges is essential for the successful industrial development, commercialization and clinical translation of LNP. In this sense, the use of Quality-by-Design (QbD) approaches [<xref rid="B101-pharmaceutics-17-00178" ref-type="bibr">101</xref>], machine learning [<xref rid="B103-pharmaceutics-17-00178" ref-type="bibr">103</xref>] and process analytical tools, combined with advanced production techniques [<xref rid="B104-pharmaceutics-17-00178" ref-type="bibr">104</xref>], means it is possible for LNP to reach the market in the near future. Using natural products brings additional challenges to standardizing the chemical characterization of nanoformulations. Some factors, such as the geographic origin, climate, extraction methods and harvest time, can affect the chemical composition and quality of an EO [<xref rid="B105-pharmaceutics-17-00178" ref-type="bibr">105</xref>]. In addition, green extraction techniques should be promoted for the large-scale harvesting of natural products. This will help to preserve biodiversity by focusing on using sustainable practices without compromising the extraction yields. Innovative technologies, such as ultrasound, microwave, or subcritical and supercritical fluid extraction must be employed [<xref rid="B106-pharmaceutics-17-00178" ref-type="bibr">106</xref>]. Furthermore, continuous efforts to harmonize regulatory issues for the clinical trials of LNP at a global level are crucial to allow for significant industrial production [<xref rid="B101-pharmaceutics-17-00178" ref-type="bibr">101</xref>].</p></sec><sec sec-type="conclusions" id="sec4-pharmaceutics-17-00178"><title>4. Conclusions</title><p>Lipid-nanoparticle-based essential oils represent an innovative approach with high potential to be explored for the development of alternative antimicrobial formulations. Such systems are excellent for the encapsulation of EO, protecting them from light, oxidation and hydrolysis, thus preserving their bioactivity. The analyzed reports confirmed that these nanosystems can be explored in a wide field of applications. They can be used in human health as antimicrobial treatments, topical disinfectants, sanitizers or antiseptics; in animal health as an alternative use of synthetic antibiotics, antifungals and antivirals; and in agriculture to control pests that affect different types of plants. However, more research is still needed to evaluate the shelf time and safety of these nanosystems, as well as their potential impacts on the environment.</p></sec><sec id="sec5-pharmaceutics-17-00178"><title>5. Perspectives</title><p>In the last few years, the world has been facing different health emergencies, which resulted in the COVID-19 pandemic together with different drug multiresistant microbial species, which has caused millions of deaths and public spending on hospitalizations and ICUs. Many efforts have been focused on the search for new antimicrobials candidates that can be effective against such mutant microbial species. However, the deaths related to generalized infections and sepsis have been exponentially growing around the world.</p><p>The ancient science is robust in demonstrating the effectiveness of diverse plant species against different pathogens that affect human, environment and animal health. Moreover, it was clear that processing such biological compounds in nanostructured systems improved their physicochemical, pharmacokinetics and pharmacodynamics properties, which resulted in formulations that can be administered using several routes or clinical and industrial surfaces.</p><p>Considering the urgency of the development of new drugs, the lack of specific regulation for the approval of proven safe and effective nanodrugs is the major challenge to be overcome around the world. Specifically in the case of LPN, the commonly used excipients are GRAS and those widely employed by food and cosmetic industries: such systems are biodegradable, do not accumulate in visceral organs such that they cause systemic toxicity; the storage, transport and distribution do not require special conditions; and they are easily scaled up with a long-term shelf life, which results in low-cost industrial production. In order to advance the industrial developments of such forms, the triple helix approach should be explored to combine multidisciplinary efforts of the universities, regulatory agencies and industries to provide standardization of the production, evaluation and waste disposal methods for scalable nanostructured drugs. The recognition of nanoformulations as commercially safe and effective drugs is important.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, E.F.d.S. and L.N.d.M.R.; methodology, E.F.d.S. and L.N.d.M.R.; formal analysis, L.N.d.M.R.; resources, L.N.d.M.R. and L.M.B.; writing, E.F.d.S., F.A.L.d.S., H.M.P. and L.N.d.M.R.; visualization, E.F.d.S.; supervision, L.N.d.M.R.; project administration, L.N.d.M.R.; funding acquisition, L.N.d.M.R. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceutics-17-00178"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Katopodi</surname><given-names>A.</given-names></name>
<name><surname>Detsi</surname><given-names>A.</given-names></name>
</person-group><article-title>Solid Lipid Nanoparticles and Nanostructured Lipid Carriers of natural products as promising systems for their bioactivity enhancement: The case of essential oils and flavonoids</article-title><source>Colloids Surf. A Physicochem. Eng. Asp.</source><year>2021</year><volume>630</volume><fpage>127529</fpage><pub-id pub-id-type="doi">10.1016/j.colsurfa.2021.127529</pub-id></element-citation></ref><ref id="B2-pharmaceutics-17-00178"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weisany</surname><given-names>W.</given-names></name>
<name><surname>Yousefi</surname><given-names>S.</given-names></name>
<name><surname>Tahir</surname><given-names>N.A.-R.</given-names></name>
<name><surname>Golestanehzadeh</surname><given-names>N.</given-names></name>
<name><surname>McClements</surname><given-names>D.J.</given-names></name>
<name><surname>Adhikari</surname><given-names>B.</given-names></name>
<name><surname>Ghasemlou</surname><given-names>M.</given-names></name>
</person-group><article-title>Targeted delivery and controlled released of essential oils using nanoencapsulation: A review</article-title><source>Adv. Colloid Interface Sci.</source><year>2022</year><volume>303</volume><fpage>102655</fpage><pub-id pub-id-type="doi">10.1016/j.cis.2022.102655</pub-id><pub-id pub-id-type="pmid">35364434</pub-id>
</element-citation></ref><ref id="B3-pharmaceutics-17-00178"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thiruvengadam</surname><given-names>M.</given-names></name>
<name><surname>Chi</surname><given-names>H.Y.</given-names></name>
<name><surname>Kim</surname><given-names>S.-H.</given-names></name>
</person-group><article-title>Impact of nanopollution on plant growth, photosynthesis, toxicity, and metabolism in the agricultural sector: An updated review</article-title><source>Plant Physiol. Biochem.</source><year>2024</year><volume>207</volume><elocation-id>108370</elocation-id><pub-id pub-id-type="doi">10.1016/j.plaphy.2024.108370</pub-id><pub-id pub-id-type="pmid">38271861</pub-id>
</element-citation></ref><ref id="B4-pharmaceutics-17-00178"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Joyce</surname><given-names>P.</given-names></name>
<name><surname>Allen</surname><given-names>C.J.</given-names></name>
<name><surname>Alonso</surname><given-names>M.J.</given-names></name>
<name><surname>Ashford</surname><given-names>M.</given-names></name>
<name><surname>Bradbury</surname><given-names>M.S.</given-names></name>
<name><surname>Germain</surname><given-names>M.</given-names></name>
<name><surname>Kavallaris</surname><given-names>M.</given-names></name>
<name><surname>Langer</surname><given-names>R.</given-names></name>
<name><surname>Lammers</surname><given-names>T.</given-names></name>
<name><surname>Peracchia</surname><given-names>M.T.</given-names></name>
<etal/>
</person-group><article-title>A translational framework to DELIVER nanomedicines to the clinic</article-title><source>Nat. Nanotechnol.</source><year>2024</year><volume>19</volume><fpage>1597</fpage><lpage>1611</lpage><pub-id pub-id-type="doi">10.1038/s41565-024-01754-7</pub-id><pub-id pub-id-type="pmid">39242807</pub-id>
</element-citation></ref><ref id="B5-pharmaceutics-17-00178"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Paramasivam</surname><given-names>G.</given-names></name>
<name><surname>Sanmugam</surname><given-names>A.</given-names></name>
<name><surname>Palem</surname><given-names>V.V.</given-names></name>
<name><surname>Sevanan</surname><given-names>M.</given-names></name>
<name><surname>Sairam</surname><given-names>A.B.</given-names></name>
<name><surname>Nachiappan</surname><given-names>N.</given-names></name>
<name><surname>Youn</surname><given-names>B.</given-names></name>
<name><surname>Lee</surname><given-names>J.S.</given-names></name>
<name><surname>Nallal</surname><given-names>M.</given-names></name>
<name><surname>Park</surname><given-names>K.H.</given-names></name>
</person-group><article-title>Nanomaterials for detection of biomolecules and delivering therapeutic agents in theragnosis: A review</article-title><source>Int. J. Biol. Macromol.</source><year>2024</year><volume>254</volume><elocation-id>127904</elocation-id><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2023.127904</pub-id><pub-id pub-id-type="pmid">37939770</pub-id>
</element-citation></ref><ref id="B6-pharmaceutics-17-00178"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dupuis</surname><given-names>V.</given-names></name>
<name><surname>Cerbu</surname><given-names>C.</given-names></name>
<name><surname>Witkowski</surname><given-names>L.</given-names></name>
<name><surname>Potarniche</surname><given-names>A.-V.</given-names></name>
<name><surname>Timar</surname><given-names>M.C.</given-names></name>
<name><surname>&#x0017b;ychska</surname><given-names>M.</given-names></name>
<name><surname>Sabliov</surname><given-names>C.M.</given-names></name>
</person-group><article-title>Nanodelivery of essential oils as efficient tools against antimicrobial resistance: A review of the type and physical-chemical properties of the delivery systems and applications</article-title><source>Drug Deliv.</source><year>2022</year><volume>29</volume><fpage>1007</fpage><lpage>1024</lpage><pub-id pub-id-type="doi">10.1080/10717544.2022.2056663</pub-id><pub-id pub-id-type="pmid">35363104</pub-id>
</element-citation></ref><ref id="B7-pharmaceutics-17-00178"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guidotti-Takeuchi</surname><given-names>M.</given-names></name>
<name><surname>de Morais Ribeiro</surname><given-names>L.N.</given-names></name>
<name><surname>dos Santos</surname><given-names>F.A.L.</given-names></name>
<name><surname>Rossi</surname><given-names>D.A.</given-names></name>
<name><surname>Lucia</surname><given-names>F.D.</given-names></name>
<name><surname>de Melo</surname><given-names>R.T.</given-names></name>
</person-group><article-title>Essential Oil-Based Nanoparticles as Antimicrobial Agents in the Food Industry</article-title><source>Microorganisms</source><year>2022</year><volume>10</volume><elocation-id>1504</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms10081504</pub-id><pub-id pub-id-type="pmid">35893562</pub-id>
</element-citation></ref><ref id="B8-pharmaceutics-17-00178"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jampilek</surname><given-names>J.</given-names></name>
<name><surname>Kralova</surname><given-names>K.</given-names></name>
</person-group><article-title>Anticancer Applications of Essential Oils Formulated into Lipid-Based Delivery Nanosystems</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><elocation-id>2681</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14122681</pub-id><pub-id pub-id-type="pmid">36559176</pub-id>
</element-citation></ref><ref id="B9-pharmaceutics-17-00178"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Radwan</surname><given-names>I.T.</given-names></name>
<name><surname>Baz</surname><given-names>M.M.</given-names></name>
<name><surname>Khater</surname><given-names>H.</given-names></name>
<name><surname>Selim</surname><given-names>A.M.</given-names></name>
</person-group><article-title>Nanostructured Lipid Carriers (NLC) for Biologically Active Green Tea and Fennel Natural Oils Delivery: Larvicidal and Adulticidal Activities against <italic toggle="yes">Culex pipiens</italic></article-title><source>Molecules</source><year>2022</year><volume>27</volume><elocation-id>1939</elocation-id><pub-id pub-id-type="doi">10.3390/molecules27061939</pub-id><pub-id pub-id-type="pmid">35335302</pub-id>
</element-citation></ref><ref id="B10-pharmaceutics-17-00178"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gugleva</surname><given-names>V.</given-names></name>
<name><surname>Ivanova</surname><given-names>N.</given-names></name>
<name><surname>Sotirova</surname><given-names>Y.</given-names></name>
<name><surname>Andonova</surname><given-names>V.</given-names></name>
</person-group><article-title>Dermal drug delivery of phytochemicals with phenolic structure via lipid-based nanotechnologies</article-title><source>Pharmaceuticals</source><year>2021</year><volume>14</volume><elocation-id>837</elocation-id><pub-id pub-id-type="doi">10.3390/ph14090837</pub-id><pub-id pub-id-type="pmid">34577536</pub-id>
</element-citation></ref><ref id="B11-pharmaceutics-17-00178"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Morais Ribeiro</surname><given-names>L.N.</given-names></name>
<name><surname>de Paula</surname><given-names>E.</given-names></name>
<name><surname>Rossi</surname><given-names>D.A.</given-names></name>
<name><surname>Monteiro</surname><given-names>G.P.</given-names></name>
<name><surname>J&#x000fa;nior</surname><given-names>E.C.V.</given-names></name>
<name><surname>Silva</surname><given-names>R.R.</given-names></name>
<name><surname>Franco</surname><given-names>R.R.</given-names></name>
<name><surname>Esp&#x000ed;ndola</surname><given-names>F.S.</given-names></name>
<name><surname>Goulart</surname><given-names>L.R.</given-names></name>
<name><surname>Fonseca</surname><given-names>B.B.</given-names></name>
</person-group><article-title>Hybrid pectin-liposome formulation against multi-resistant bacterial strains</article-title><source>Pharmaceutics</source><year>2020</year><volume>12</volume><elocation-id>769</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics12080769</pub-id><pub-id pub-id-type="pmid">32823823</pub-id>
</element-citation></ref><ref id="B12-pharmaceutics-17-00178"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garc&#x000ed;a-Pinel</surname><given-names>B.</given-names></name>
<name><surname>Porras-Alcal&#x000e1;</surname><given-names>C.</given-names></name>
<name><surname>Ortega-Rodr&#x000ed;guez</surname><given-names>A.</given-names></name>
<name><surname>Sarabia</surname><given-names>F.</given-names></name>
<name><surname>Prados</surname><given-names>J.</given-names></name>
<name><surname>Melguizo</surname><given-names>C.</given-names></name>
<name><surname>L&#x000f3;pez-Romero</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Lipid-based nanoparticles: Application and recent advances in cancer treatment</article-title><source>Nanomaterials</source><year>2019</year><volume>9</volume><elocation-id>638</elocation-id><pub-id pub-id-type="doi">10.3390/nano9040638</pub-id><pub-id pub-id-type="pmid">31010180</pub-id>
</element-citation></ref><ref id="B13-pharmaceutics-17-00178"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Delshadi</surname><given-names>R.</given-names></name>
<name><surname>Bahrami</surname><given-names>A.</given-names></name>
<name><surname>Tafti</surname><given-names>A.G.</given-names></name>
<name><surname>Barba</surname><given-names>F.J.</given-names></name>
<name><surname>Williams</surname><given-names>L.L.</given-names></name>
</person-group><article-title>Micro and nano-encapsulation of vegetable and essential oils to develop functional food products with improved nutritional profiles</article-title><source>Trends Food Sci. Technol.</source><year>2020</year><volume>104</volume><fpage>72</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.tifs.2020.07.004</pub-id></element-citation></ref><ref id="B14-pharmaceutics-17-00178"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Ara&#x000fa;jo</surname><given-names>D.R.</given-names></name>
<name><surname>de Morais Ribeiro</surname><given-names>L.N.</given-names></name>
<name><surname>de Paula</surname><given-names>E.</given-names></name>
</person-group><article-title>Lipid-based carriers for the delivery of local anesthetics</article-title><source>Expert Opin. Drug Deliv.</source><year>2019</year><volume>16</volume><fpage>701</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1080/17425247.2019.1629415</pub-id><pub-id pub-id-type="pmid">31172838</pub-id>
</element-citation></ref><ref id="B15-pharmaceutics-17-00178"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moammeri</surname><given-names>A.</given-names></name>
<name><surname>Chegeni</surname><given-names>M.M.</given-names></name>
<name><surname>Sahrayi</surname><given-names>H.</given-names></name>
<name><surname>Ghafelehbashi</surname><given-names>R.</given-names></name>
<name><surname>Memarzadeh</surname><given-names>F.</given-names></name>
<name><surname>Mansouri</surname><given-names>A.</given-names></name>
<name><surname>Akbarzadeh</surname><given-names>I.</given-names></name>
<name><surname>Abtahi</surname><given-names>M.S.</given-names></name>
<name><surname>Hejabi</surname><given-names>F.</given-names></name>
<name><surname>Ren</surname><given-names>Q.</given-names></name>
</person-group><article-title>Current advances in niosomes applications for drug delivery and cancer treatment</article-title><source>Mater. Today Bio</source><year>2023</year><volume>23</volume><elocation-id>100837</elocation-id><pub-id pub-id-type="doi">10.1016/j.mtbio.2023.100837</pub-id></element-citation></ref><ref id="B16-pharmaceutics-17-00178"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yasamineh</surname><given-names>S.</given-names></name>
<name><surname>Yasamineh</surname><given-names>P.</given-names></name>
<name><surname>Ghafouri Kalajahi</surname><given-names>H.</given-names></name>
<name><surname>Gholizadeh</surname><given-names>O.</given-names></name>
<name><surname>Yekanipour</surname><given-names>Z.</given-names></name>
<name><surname>Afkhami</surname><given-names>H.</given-names></name>
<name><surname>Eslami</surname><given-names>M.</given-names></name>
<name><surname>Kheirkhah</surname><given-names>A.H.</given-names></name>
<name><surname>Taghizadeh</surname><given-names>M.</given-names></name>
<name><surname>Yazdani</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>A state-of-the-art review on the recent advances of niosomes as a targeted drug delivery system</article-title><source>Int. J. Pharm.</source><year>2022</year><volume>624</volume><fpage>121878</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2022.121878</pub-id><pub-id pub-id-type="pmid">35636629</pub-id>
</element-citation></ref><ref id="B17-pharmaceutics-17-00178"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bhardwaj</surname><given-names>P.</given-names></name>
<name><surname>Tripathi</surname><given-names>P.</given-names></name>
<name><surname>Gupta</surname><given-names>R.</given-names></name>
<name><surname>Pandey</surname><given-names>S.</given-names></name>
</person-group><article-title>Niosomes: A review on niosomal research in the last decade</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2020</year><volume>56</volume><fpage>101581</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2020.101581</pub-id></element-citation></ref><ref id="B18-pharmaceutics-17-00178"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ribeiro</surname><given-names>L.N.M.</given-names></name>
<name><surname>da Silva</surname><given-names>G.H.R.</given-names></name>
<name><surname>Couto</surname><given-names>V.M.</given-names></name>
<name><surname>Castro</surname><given-names>S.R.</given-names></name>
<name><surname>Breitkreitz</surname><given-names>M.C.</given-names></name>
<name><surname>Martinez</surname><given-names>C.S.</given-names></name>
<name><surname>Igart&#x000fa;a</surname><given-names>D.E.</given-names></name>
<name><surname>Prieto</surname><given-names>M.J.</given-names></name>
<name><surname>de Paula</surname><given-names>E.</given-names></name>
</person-group><article-title>Functional Hybrid Nanoemulsions for Sumatriptan Intranasal Delivery</article-title><source>Front. Chem.</source><year>2020</year><volume>8</volume><elocation-id>589503</elocation-id><pub-id pub-id-type="doi">10.3389/fchem.2020.589503</pub-id><pub-id pub-id-type="pmid">33282832</pub-id>
</element-citation></ref><ref id="B19-pharmaceutics-17-00178"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pavoni</surname><given-names>L.</given-names></name>
<name><surname>Perinelli</surname><given-names>D.R.</given-names></name>
<name><surname>Bonacucina</surname><given-names>G.</given-names></name>
<name><surname>Cespi</surname><given-names>M.</given-names></name>
<name><surname>Palmieri</surname><given-names>G.F.</given-names></name>
</person-group><article-title>An overview of micro-and nanoemulsions as vehicles for essential oils: Formulation, preparation and stability</article-title><source>Nanomaterials</source><year>2020</year><volume>10</volume><fpage>135</fpage><pub-id pub-id-type="doi">10.3390/nano10010135</pub-id><pub-id pub-id-type="pmid">31940900</pub-id>
</element-citation></ref><ref id="B20-pharmaceutics-17-00178"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pires</surname><given-names>H.M.</given-names></name>
<name><surname>Bastos</surname><given-names>L.M.</given-names></name>
<name><surname>da Silva</surname><given-names>E.F.</given-names></name>
<name><surname>Fonseca</surname><given-names>B.B.</given-names></name>
<name><surname>Sommerfeld</surname><given-names>S.</given-names></name>
<name><surname>de Oliveira Junior</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Antimicrobial Activity of Essential-Oil-Based Nanostructured Lipid Carriers against <italic toggle="yes">Campylobacter</italic> Spp. Isolated from Chicken Carcasses</article-title><source>Pharmaceutics</source><year>2024</year><volume>16</volume><elocation-id>922</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics16070922</pub-id><pub-id pub-id-type="pmid">39065619</pub-id>
</element-citation></ref><ref id="B21-pharmaceutics-17-00178"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Najjari</surname><given-names>N.</given-names></name>
<name><surname>Sari</surname><given-names>S.</given-names></name>
<name><surname>Saffari</surname><given-names>M.</given-names></name>
<name><surname>Kelidari</surname><given-names>H.</given-names></name>
<name><surname>Nokhodchi</surname><given-names>A.</given-names></name>
</person-group><article-title>Formulation optimization and characterization of <italic toggle="yes">Pistacia atlantica</italic> Desf. essential oil-loaded nanostructured lipid carriers on the proliferation of human breast cancer cell line SKBR3 (in vitro studies)</article-title><source>J. Herb. Med.</source><year>2022</year><volume>36</volume><fpage>100600</fpage><pub-id pub-id-type="doi">10.1016/j.hermed.2022.100600</pub-id></element-citation></ref><ref id="B22-pharmaceutics-17-00178"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lammari</surname><given-names>N.</given-names></name>
<name><surname>Louaer</surname><given-names>O.</given-names></name>
<name><surname>Meniai</surname><given-names>A.H.</given-names></name>
<name><surname>Fessi</surname><given-names>H.</given-names></name>
<name><surname>Elaissari</surname><given-names>A.</given-names></name>
</person-group><article-title>Plant oils: From chemical composition to encapsulated form use</article-title><source>Int. J. Pharm.</source><year>2021</year><volume>601</volume><fpage>120538</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2021.120538</pub-id><pub-id pub-id-type="pmid">33781879</pub-id>
</element-citation></ref><ref id="B23-pharmaceutics-17-00178"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Morais Ribeiro</surname><given-names>L.N.</given-names></name>
<name><surname>de Paula</surname><given-names>E.</given-names></name>
<name><surname>Rossi</surname><given-names>D.A.</given-names></name>
<name><surname>Martins</surname><given-names>F.A.</given-names></name>
<name><surname>de Melo</surname><given-names>R.T.</given-names></name>
<name><surname>Monteiro</surname><given-names>G.P.</given-names></name>
<name><surname>Breitkreitz</surname><given-names>M.C.</given-names></name>
<name><surname>Goulart</surname><given-names>L.R.</given-names></name>
<name><surname>Fonseca</surname><given-names>B.B.</given-names></name>
</person-group><article-title>Nanocarriers From Natural Lipids With In Vitro Activity Against <italic toggle="yes">Campylobacter jejuni</italic></article-title><source>Front. Cell. Infect. Microbiol.</source><year>2021</year><volume>10</volume><elocation-id>571040</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2020.571040</pub-id><pub-id pub-id-type="pmid">33489930</pub-id>
</element-citation></ref><ref id="B24-pharmaceutics-17-00178"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Viegas</surname><given-names>C.</given-names></name>
<name><surname>Patr&#x000ed;cio</surname><given-names>A.B.</given-names></name>
<name><surname>Prata</surname><given-names>J.M.</given-names></name>
<name><surname>Nadhman</surname><given-names>A.</given-names></name>
<name><surname>Chintamaneni</surname><given-names>P.K.</given-names></name>
<name><surname>Fonte</surname><given-names>P.</given-names></name>
</person-group><article-title>Solid Lipid Nanoparticles vs. Nanostructured Lipid Carriers: A Comparative Review</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><elocation-id>1593</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics15061593</pub-id><pub-id pub-id-type="pmid">37376042</pub-id>
</element-citation></ref><ref id="B25-pharmaceutics-17-00178"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stefanov</surname><given-names>S.R.</given-names></name>
<name><surname>Andonova</surname><given-names>V.Y.</given-names></name>
</person-group><article-title>Lipid Nanoparticulate Drug Delivery Systems: Recent Advances in the Treatment of Skin Disorders</article-title><source>Pharmaceuticals</source><year>2021</year><volume>14</volume><elocation-id>1083</elocation-id><pub-id pub-id-type="doi">10.3390/ph14111083</pub-id><pub-id pub-id-type="pmid">34832865</pub-id>
</element-citation></ref><ref id="B26-pharmaceutics-17-00178"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Namiot</surname><given-names>E.D.</given-names></name>
<name><surname>Sokolov</surname><given-names>A.V.</given-names></name>
<name><surname>Chubarev</surname><given-names>V.N.</given-names></name>
<name><surname>Tarasov</surname><given-names>V.V.</given-names></name>
<name><surname>Schi&#x000f6;th</surname><given-names>H.B.</given-names></name>
</person-group><article-title>Nanoparticles in Clinical Trials: Analysis of Clinical Trials, FDA Approvals and Use for COVID-19 Vaccines</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>787</elocation-id><pub-id pub-id-type="doi">10.3390/ijms24010787</pub-id><pub-id pub-id-type="pmid">36614230</pub-id>
</element-citation></ref><ref id="B27-pharmaceutics-17-00178"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thi</surname><given-names>T.T.H.</given-names></name>
<name><surname>Suys</surname><given-names>E.J.A.</given-names></name>
<name><surname>Lee</surname><given-names>J.S.</given-names></name>
<name><surname>Nguyen</surname><given-names>D.H.</given-names></name>
<name><surname>Park</surname><given-names>K.D.</given-names></name>
<name><surname>Truong</surname><given-names>N.P.</given-names></name>
</person-group><article-title>Lipid-based nanoparticles in the clinic and clinical trials: From cancer nanomedicine to COVID-19 vaccines</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>359</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9040359</pub-id><pub-id pub-id-type="pmid">33918072</pub-id>
</element-citation></ref><ref id="B28-pharmaceutics-17-00178"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chatzikleanthous</surname><given-names>D.</given-names></name>
<name><surname>O&#x02019;Hagan</surname><given-names>D.T.</given-names></name>
<name><surname>Adamo</surname><given-names>R.</given-names></name>
</person-group><article-title>Lipid-Based Nanoparticles for Delivery of Vaccine Adjuvants and Antigens: Toward Multicomponent Vaccines</article-title><source>Mol. Pharm.</source><year>2021</year><volume>18</volume><fpage>2867</fpage><lpage>2888</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.1c00447</pub-id><pub-id pub-id-type="pmid">34264684</pub-id>
</element-citation></ref><ref id="B29-pharmaceutics-17-00178"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pimentel</surname><given-names>L.S.</given-names></name>
<name><surname>Bastos</surname><given-names>L.M.</given-names></name>
<name><surname>Goulart</surname><given-names>L.R.</given-names></name>
<name><surname>de Morais Ribeiro</surname><given-names>L.N.</given-names></name>
</person-group><article-title>Therapeutic Effects of Essential Oils and Their Bioactive Compounds on Prostate Cancer Treatment</article-title><source>Pharmaceutics</source><year>2024</year><volume>16</volume><elocation-id>583</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics16050583</pub-id><pub-id pub-id-type="pmid">38794244</pub-id>
</element-citation></ref><ref id="B30-pharmaceutics-17-00178"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sattayakhom</surname><given-names>A.</given-names></name>
<name><surname>Wichit</surname><given-names>S.</given-names></name>
<name><surname>Koomhin</surname><given-names>P.</given-names></name>
</person-group><article-title>The Effects of Essential Oils on the Nervous System: A Scoping Review</article-title><source>Molecules</source><year>2023</year><volume>28</volume><elocation-id>3771</elocation-id><pub-id pub-id-type="doi">10.3390/molecules28093771</pub-id><pub-id pub-id-type="pmid">37175176</pub-id>
</element-citation></ref><ref id="B31-pharmaceutics-17-00178"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dongre</surname><given-names>P.</given-names></name>
<name><surname>Doifode</surname><given-names>C.</given-names></name>
<name><surname>Choudhary</surname><given-names>S.</given-names></name>
<name><surname>Sharma</surname><given-names>N.</given-names></name>
</person-group><article-title>Botanical description, chemical composition, traditional uses and pharmacology of <italic toggle="yes">Citrus sinensis</italic>: An updated review</article-title><source>Pharmacol. Res. Mod. Chin. Med.</source><year>2023</year><volume>8</volume><fpage>100272</fpage><pub-id pub-id-type="doi">10.1016/j.prmcm.2023.100272</pub-id></element-citation></ref><ref id="B32-pharmaceutics-17-00178"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Haro-Gonz&#x000e1;lez</surname><given-names>J.N.</given-names></name>
<name><surname>Castillo-Herrera</surname><given-names>G.A.</given-names></name>
<name><surname>Mart&#x000ed;nez-Vel&#x000e1;zquez</surname><given-names>M.</given-names></name>
<name><surname>Espinosa-Andrews</surname><given-names>H.</given-names></name>
</person-group><article-title>Clove essential oil (<italic toggle="yes">Syzygium aromaticum</italic> L. myrtaceae): Extraction, chemical composition, food applications, and essential bioactivity for human health</article-title><source>Molecules</source><year>2021</year><volume>26</volume><elocation-id>6387</elocation-id><pub-id pub-id-type="doi">10.3390/molecules26216387</pub-id><pub-id pub-id-type="pmid">34770801</pub-id>
</element-citation></ref><ref id="B33-pharmaceutics-17-00178"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pimentel</surname><given-names>L.S.</given-names></name>
<name><surname>Sommerfeld</surname><given-names>S.</given-names></name>
<name><surname>de Sousa Braga</surname><given-names>P.F.</given-names></name>
<name><surname>Coleto</surname><given-names>A.F.</given-names></name>
<name><surname>Fonseca</surname><given-names>B.B.</given-names></name>
<name><surname>Bastos</surname><given-names>L.M.</given-names></name>
<name><surname>Goulart</surname><given-names>L.R.</given-names></name>
<name><surname>de Morais Ribeiro</surname><given-names>L.N.</given-names></name>
</person-group><article-title>Antitumor activity of essential oils-based nanostructured lipid carriers on prostate cancer cells</article-title><source>Int. J. Pharm.</source><year>2024</year><volume>657</volume><fpage>124149</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2024.124149</pub-id><pub-id pub-id-type="pmid">38677395</pub-id>
</element-citation></ref><ref id="B34-pharmaceutics-17-00178"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sawatphakdee</surname><given-names>G.</given-names></name>
<name><surname>Yostawonkul</surname><given-names>J.</given-names></name>
<name><surname>Oontawee</surname><given-names>S.</given-names></name>
<name><surname>Rodprasert</surname><given-names>W.</given-names></name>
<name><surname>Sawangmake</surname><given-names>C.</given-names></name>
<name><surname>Kornsuthisopon</surname><given-names>C.</given-names></name>
<name><surname>Yata</surname><given-names>T.</given-names></name>
<name><surname>Tabtieang</surname><given-names>S.P.</given-names></name>
<name><surname>Nowwarote</surname><given-names>N.</given-names></name>
<name><surname>Pirarat</surname><given-names>N.</given-names></name>
</person-group><article-title>Feasibility of Nanostructured Lipid Carrier Loaded with Alpha-Mangostin and Clove Oil for Canine Periodontal Therapy</article-title><source>Animals</source><year>2024</year><volume>14</volume><elocation-id>2084</elocation-id><pub-id pub-id-type="doi">10.3390/ani14142084</pub-id><pub-id pub-id-type="pmid">39061546</pub-id>
</element-citation></ref><ref id="B35-pharmaceutics-17-00178"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>M&#x000fa;nera-Echeverri</surname><given-names>A.</given-names></name>
<name><surname>M&#x000fa;nera-Echeverri</surname><given-names>J.L.</given-names></name>
<name><surname>Segura-S&#x000e1;nchez</surname><given-names>F.</given-names></name>
</person-group><article-title>Bio-Pesticidal Potential of Nanostructured Lipid Carriers Loaded with Thyme and Rosemary Essential Oils against Common Ornamental Flower Pests</article-title><source>Colloids Interfaces</source><year>2024</year><volume>8</volume><elocation-id>55</elocation-id><pub-id pub-id-type="doi">10.3390/colloids8050055</pub-id></element-citation></ref><ref id="B36-pharmaceutics-17-00178"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Geronimo</surname><given-names>G.</given-names></name>
<name><surname>da Silva</surname><given-names>G.H.R.</given-names></name>
<name><surname>de Moura</surname><given-names>L.D.</given-names></name>
<name><surname>Ribeiro</surname><given-names>L.N.M.</given-names></name>
<name><surname>A Guilherme</surname><given-names>V.</given-names></name>
<name><surname>Mendon&#x000e7;a</surname><given-names>T.C.</given-names></name>
<name><surname>Castro</surname><given-names>S.R.</given-names></name>
<name><surname>Breitkreitz</surname><given-names>M.C.</given-names></name>
<name><surname>de Paula</surname><given-names>E.</given-names></name>
</person-group><article-title>Development of S75:R25 bupivacaine-loaded lipid nanoparticles functionalized with essential oils for treating melanoma</article-title><source>J. Chem. Technol. Biotechnol.</source><year>2021</year><volume>96</volume><fpage>2197</fpage><lpage>2207</lpage><pub-id pub-id-type="doi">10.1002/jctb.6715</pub-id></element-citation></ref><ref id="B37-pharmaceutics-17-00178"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shah</surname><given-names>S.</given-names></name>
<name><surname>Dhawan</surname><given-names>V.</given-names></name>
<name><surname>Holm</surname><given-names>R.</given-names></name>
<name><surname>Nagarsenker</surname><given-names>M.S.</given-names></name>
<name><surname>Perrie</surname><given-names>Y.</given-names></name>
</person-group><article-title>Liposomes: Advancements and innovation in the manufacturing process</article-title><source>Adv. Drug Deliv. Rev.</source><year>2020</year><volume>154&#x02013;155</volume><fpage>102</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2020.07.002</pub-id></element-citation></ref><ref id="B38-pharmaceutics-17-00178"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bedoya-Agudelo</surname><given-names>J.P.</given-names></name>
<name><surname>L&#x000f3;pez-Carvajal</surname><given-names>J.E.</given-names></name>
<name><surname>Quiguan&#x000e1;s-Guar&#x000ed;n</surname><given-names>E.S.</given-names></name>
<name><surname>Cardona</surname><given-names>N.</given-names></name>
<name><surname>Padilla-Sanabria</surname><given-names>L.</given-names></name>
<name><surname>Casta&#x000f1;o-Osorio</surname><given-names>J.C.</given-names></name>
</person-group><article-title>Assessment of Antimicrobial and Cytotoxic Activities of Liposomes Loaded with Curcumin and <italic toggle="yes">Lippia origanoides</italic> Essential Oil</article-title><source>Biomolecules</source><year>2024</year><volume>14</volume><elocation-id>851</elocation-id><pub-id pub-id-type="doi">10.3390/biom14070851</pub-id><pub-id pub-id-type="pmid">39062565</pub-id>
</element-citation></ref><ref id="B39-pharmaceutics-17-00178"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ben-Khalifa</surname><given-names>R.</given-names></name>
<name><surname>Gaspar</surname><given-names>F.B.</given-names></name>
<name><surname>Pereira</surname><given-names>C.</given-names></name>
<name><surname>Chekir-Ghedira</surname><given-names>L.</given-names></name>
<name><surname>Rodr&#x000ed;guez-Rojo</surname><given-names>S.</given-names></name>
</person-group><article-title>Essential oil and hydrophilic antibiotic co-encapsulation in multiple lipid nanoparticles: Proof of concept and in vitro activity against <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>Antibiotics</source><year>2021</year><volume>10</volume><elocation-id>1300</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics10111300</pub-id><pub-id pub-id-type="pmid">34827238</pub-id>
</element-citation></ref><ref id="B40-pharmaceutics-17-00178"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fahimnia</surname><given-names>F.</given-names></name>
<name><surname>Nemattalab</surname><given-names>M.</given-names></name>
<name><surname>Hesari</surname><given-names>Z.</given-names></name>
</person-group><article-title>Development and characterization of a topical gel, containing lavender <italic toggle="yes">(Lavandula angustifolia</italic>) oil loaded solid lipid nanoparticles</article-title><source>BMC Complement. Med. Ther.</source><year>2024</year><volume>24</volume><elocation-id>155</elocation-id><pub-id pub-id-type="doi">10.1186/s12906-024-04440-2</pub-id><pub-id pub-id-type="pmid">38589838</pub-id>
</element-citation></ref><ref id="B41-pharmaceutics-17-00178"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moghadam</surname><given-names>R.N.</given-names></name>
<name><surname>Majdizadeh</surname><given-names>M.</given-names></name>
<name><surname>Golbashy</surname><given-names>M.</given-names></name>
<name><surname>Haghiralsadat</surname><given-names>F.</given-names></name>
<name><surname>Hemati</surname><given-names>M.</given-names></name>
</person-group><article-title>Laboratory study: Synthesis and optimization of nano nisomes containing <italic toggle="yes">Bunium persicum</italic> essential oil and investigating its toxicity on <italic toggle="yes">Trichomonas vaginalis</italic> parasite and HFF cell line</article-title><source>Heliyon</source><year>2024</year><volume>10</volume><fpage>e35967</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2024.e35967</pub-id><pub-id pub-id-type="pmid">39224365</pub-id>
</element-citation></ref><ref id="B42-pharmaceutics-17-00178"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Fu</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Feng</surname><given-names>S.</given-names></name>
<name><surname>Zhao</surname><given-names>Z.</given-names></name>
<name><surname>Zheng</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Peng</surname><given-names>Y.</given-names></name>
</person-group><article-title>In vivo anti-hepatitis B activity of <italic toggle="yes">Artemisia argyi</italic> essential oil-loaded nanostructured lipid carriers. Study of its mechanism of action by network pharmacology and molecular docking</article-title><source>Phytomedicine</source><year>2023</year><volume>116</volume><fpage>154848</fpage><pub-id pub-id-type="doi">10.1016/j.phymed.2023.154848</pub-id><pub-id pub-id-type="pmid">37163901</pub-id>
</element-citation></ref><ref id="B43-pharmaceutics-17-00178"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>da Silva</surname><given-names>E.F.</given-names></name>
<name><surname>Bastos</surname><given-names>L.M.</given-names></name>
<name><surname>Fonseca</surname><given-names>B.B.</given-names></name>
<name><surname>Ribas</surname><given-names>R.M.</given-names></name>
<name><surname>Sommerfeld</surname><given-names>S.</given-names></name>
<name><surname>Pires</surname><given-names>H.M.</given-names></name>
<name><surname>dos Santos</surname><given-names>F.A.L.</given-names></name>
<name><surname>de Morais Ribeiro</surname><given-names>L.N.</given-names></name>
</person-group><article-title>Lipid nanoparticles based on natural matrices with activity against multidrug resistant bacterial species</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2024</year><volume>13</volume><elocation-id>1328519</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2023.1328519</pub-id><pub-id pub-id-type="pmid">38264725</pub-id>
</element-citation></ref><ref id="B44-pharmaceutics-17-00178"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cecchini</surname><given-names>M.</given-names></name>
<name><surname>Paoloni</surname><given-names>C.</given-names></name>
<name><surname>Campra</surname><given-names>N.</given-names></name>
<name><surname>Picco</surname><given-names>N.</given-names></name>
<name><surname>Grosso</surname><given-names>M.</given-names></name>
<name><surname>Perez</surname><given-names>M.S.</given-names></name>
<name><surname>Alustiza</surname><given-names>F.</given-names></name>
<name><surname>Cariddi</surname><given-names>N.</given-names></name>
<name><surname>Bellingeri</surname><given-names>R.</given-names></name>
</person-group><article-title>Nanoemulsion of <italic toggle="yes">Minthostachys verticillata</italic> essential oil. In-vitro evaluation of its antibacterial activity</article-title><source>Heliyon</source><year>2021</year><volume>7</volume><fpage>e05896</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2021.e05896</pub-id><pub-id pub-id-type="pmid">33521347</pub-id>
</element-citation></ref><ref id="B45-pharmaceutics-17-00178"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Barros</surname><given-names>D.P.C.</given-names></name>
<name><surname>Reed</surname><given-names>P.</given-names></name>
<name><surname>Alves</surname><given-names>M.</given-names></name>
<name><surname>Santos</surname><given-names>R.</given-names></name>
<name><surname>Oliva</surname><given-names>A.</given-names></name>
</person-group><article-title>Biocompatibility and antimicrobial activity of nanostructured lipid carriers for topical applications are affected by type of oils used in their composition</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><elocation-id>1950</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics13111950</pub-id><pub-id pub-id-type="pmid">34834365</pub-id>
</element-citation></ref><ref id="B46-pharmaceutics-17-00178"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rodenak-Kladniew</surname><given-names>B.</given-names></name>
<name><surname>Castro</surname><given-names>M.A.</given-names></name>
<name><surname>Gambaro</surname><given-names>R.C.</given-names></name>
<name><surname>Girotti</surname><given-names>J.</given-names></name>
<name><surname>Cisneros</surname><given-names>J.S.</given-names></name>
<name><surname>Vi&#x000f1;a</surname><given-names>S.</given-names></name>
<name><surname>Padula</surname><given-names>G.</given-names></name>
<name><surname>Crespo</surname><given-names>R.</given-names></name>
<name><surname>Castro</surname><given-names>G.R.</given-names></name>
<name><surname>Gehring</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Cytotoxic Screening and Enhanced Anticancer Activity of <italic toggle="yes">Lippia alba</italic> and <italic toggle="yes">Clinopodium nepeta</italic> Essential Oils-Loaded Biocompatible Lipid Nanoparticles against Lung and Colon Cancer Cells</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><elocation-id>2045</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics15082045</pub-id><pub-id pub-id-type="pmid">37631258</pub-id>
</element-citation></ref><ref id="B47-pharmaceutics-17-00178"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abedinpour</surname><given-names>N.</given-names></name>
<name><surname>Ghanbariasad</surname><given-names>A.</given-names></name>
<name><surname>Taghinezhad</surname><given-names>A.</given-names></name>
<name><surname>Osanloo</surname><given-names>M.</given-names></name>
</person-group><article-title>Preparation of Nanoemulsions of <italic toggle="yes">Mentha piperita</italic> Essential Oil and Investigation of Their Cytotoxic Effect on Human Breast Cancer Lines</article-title><source>Bionanoscience</source><year>2021</year><volume>11</volume><fpage>428</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1007/s12668-021-00827-4</pub-id></element-citation></ref><ref id="B48-pharmaceutics-17-00178"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rad</surname><given-names>E.Y.</given-names></name>
<name><surname>Tabrizi</surname><given-names>M.H.</given-names></name>
<name><surname>Ardalan</surname><given-names>P.</given-names></name>
<name><surname>Seyedi</surname><given-names>S.M.R.</given-names></name>
<name><surname>Yadamani</surname><given-names>S.</given-names></name>
<name><surname>Zamani-Esmati</surname><given-names>P.</given-names></name>
<name><surname>Sereshkeh</surname><given-names>N.H.</given-names></name>
</person-group><article-title><italic toggle="yes">Citrus lemon</italic> essential oil nanoemulsion (CLEO-NE), a safe cell-depended apoptosis inducer in human A549 lung cancer cells with anti-angiogenic activity</article-title><source>J. Microencapsul.</source><year>2020</year><volume>37</volume><fpage>394</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1080/02652048.2020.1767223</pub-id><pub-id pub-id-type="pmid">32400238</pub-id>
</element-citation></ref><ref id="B49-pharmaceutics-17-00178"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Guo</surname><given-names>X.</given-names></name>
<name><surname>Sun</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>M.</given-names></name>
<name><surname>Tang</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Simal-Gandara</surname><given-names>J.</given-names></name>
<name><surname>Xu</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Evaluating the hypolipidemic effect of garlic essential oil encapsulated in a novel double-layer delivery system</article-title><source>Colloids Surf. B Biointerfaces</source><year>2024</year><volume>237</volume><elocation-id>113835</elocation-id><pub-id pub-id-type="doi">10.1016/j.colsurfb.2024.113835</pub-id><pub-id pub-id-type="pmid">38479260</pub-id>
</element-citation></ref><ref id="B50-pharmaceutics-17-00178"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Souto</surname><given-names>E.B.</given-names></name>
<name><surname>Severino</surname><given-names>P.</given-names></name>
<name><surname>Marques</surname><given-names>C.</given-names></name>
<name><surname>Andrade</surname><given-names>L.N.</given-names></name>
<name><surname>Durazzo</surname><given-names>A.</given-names></name>
<name><surname>Lucarini</surname><given-names>M.</given-names></name>
<name><surname>Atanasov</surname><given-names>A.G.</given-names></name>
<name><surname>El Maimouni</surname><given-names>S.</given-names></name>
<name><surname>Novellino</surname><given-names>E.</given-names></name>
<name><surname>Santini</surname><given-names>A.</given-names></name>
</person-group><article-title><italic toggle="yes">Croton argyrophyllus</italic> Kunth essential oil-loaded solid lipid nanoparticles: Evaluation of release profile, antioxidant activity and cytotoxicity in a neuroblastoma cell line</article-title><source>Sustainability</source><year>2020</year><volume>12</volume><elocation-id>7697</elocation-id><pub-id pub-id-type="doi">10.3390/su12187697</pub-id></element-citation></ref><ref id="B51-pharmaceutics-17-00178"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sriramavaratharajan</surname><given-names>V.</given-names></name>
<name><surname>M-Thirusenthilarasan</surname><given-names>I.</given-names></name>
<name><surname>Nirupama</surname><given-names>R.</given-names></name>
<name><surname>Vadivel</surname><given-names>V.</given-names></name>
<name><surname>Pragadheesh</surname><given-names>V.S.</given-names></name>
<name><surname>Sundaresan</surname><given-names>V.</given-names></name>
<name><surname>Murugan</surname><given-names>R.</given-names></name>
</person-group><article-title>Volatile profiling of <italic toggle="yes">Cinnamomum heyneanum</italic> and <italic toggle="yes">Cinnamomum palghatensis</italic> and in vitro and in silico antidiabetic activity of essential oil nanoemulsions</article-title><source>Pharmacol. Res. Nat. Prod.</source><year>2024</year><volume>4</volume><fpage>100081</fpage><pub-id pub-id-type="doi">10.1016/j.prenap.2024.100081</pub-id></element-citation></ref><ref id="B52-pharmaceutics-17-00178"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kreutz</surname><given-names>T.</given-names></name>
<name><surname>Lucca</surname><given-names>L.G.</given-names></name>
<name><surname>Carneiro</surname><given-names>S.B.</given-names></name>
<name><surname>Limberger</surname><given-names>R.P.</given-names></name>
<name><surname>Veiga-Junior</surname><given-names>V.F.</given-names></name>
<name><surname>de Ara&#x000fa;jo</surname><given-names>B.V.</given-names></name>
<name><surname>Teixeira</surname><given-names>H.F.</given-names></name>
<name><surname>Koester</surname><given-names>L.S.</given-names></name>
</person-group><article-title>Hydrogel-thickened nanoemulsion containing amazonian <italic toggle="yes">Aniba canelilla</italic> (Kunth) Mez essential oil: Skin permeation and in vivo anti-inflammatory efficacy</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2023</year><volume>87</volume><fpage>104771</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2023.104771</pub-id></element-citation></ref><ref id="B53-pharmaceutics-17-00178"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scuteri</surname><given-names>D.</given-names></name>
<name><surname>Cassano</surname><given-names>R.</given-names></name>
<name><surname>Trombino</surname><given-names>S.</given-names></name>
<name><surname>Russo</surname><given-names>R.</given-names></name>
<name><surname>Mizoguchi</surname><given-names>H.</given-names></name>
<name><surname>Watanabe</surname><given-names>C.</given-names></name>
<name><surname>Hamamura</surname><given-names>K.</given-names></name>
<name><surname>Katsuyama</surname><given-names>S.</given-names></name>
<name><surname>Komatsu</surname><given-names>T.</given-names></name>
<name><surname>Morrone</surname><given-names>L.A.</given-names></name>
<etal/>
</person-group><article-title>Development and translation of nanobeo, a nanotechnology-based delivery system of bergamot essential oil deprived of furocumarins, in the control of agitation in severe dementia</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><elocation-id>379</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics13030379</pub-id><pub-id pub-id-type="pmid">33809385</pub-id>
</element-citation></ref><ref id="B54-pharmaceutics-17-00178"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Santos</surname><given-names>J.S.</given-names></name>
<name><surname>Galv&#x000e3;o</surname><given-names>J.G.</given-names></name>
<name><surname>Mendon&#x000e7;a</surname><given-names>M.R.</given-names></name>
<name><surname>Costa</surname><given-names>A.M.</given-names></name>
<name><surname>Silva</surname><given-names>A.R.</given-names></name>
<name><surname>Oliveira</surname><given-names>D.S.</given-names></name>
<name><surname>Santos</surname><given-names>A.d.J.</given-names></name>
<name><surname>Lira</surname><given-names>A.A.M.</given-names></name>
<name><surname>Scher</surname><given-names>R.</given-names></name>
<name><surname>J&#x000fa;nior</surname><given-names>P.A.S.</given-names></name>
<etal/>
</person-group><article-title>Encapsulation of <italic toggle="yes">Citrus sinensis</italic> essential oil and R-limonene in lipid nanocarriers: A potential strategy for the treatment of leishmaniasis</article-title><source>Int. J. Pharm.</source><year>2024</year><volume>662</volume><fpage>124464</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2024.124464</pub-id><pub-id pub-id-type="pmid">39033939</pub-id>
</element-citation></ref><ref id="B55-pharmaceutics-17-00178"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghanbariasad</surname><given-names>A.</given-names></name>
<name><surname>Valizadeh</surname><given-names>A.</given-names></name>
<name><surname>Ghadimi</surname><given-names>S.N.</given-names></name>
<name><surname>Fereidouni</surname><given-names>Z.</given-names></name>
<name><surname>Osanloo</surname><given-names>M.</given-names></name>
</person-group><article-title>Nanoformulating <italic toggle="yes">Cinnamomum zeylanicum</italic> essential oil with an extreme effect on <italic toggle="yes">Leishmania tropica</italic> and <italic toggle="yes">Leishmania major</italic></article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2021</year><volume>63</volume><fpage>102436</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2021.102436</pub-id></element-citation></ref><ref id="B56-pharmaceutics-17-00178"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Siyadatpanah</surname><given-names>A.</given-names></name>
<name><surname>Norouzi</surname><given-names>R.</given-names></name>
<name><surname>Mirzaei</surname><given-names>F.</given-names></name>
<name><surname>Haghirosadat</surname><given-names>B.F.</given-names></name>
<name><surname>Nissapatorn</surname><given-names>V.</given-names></name>
<name><surname>Mitsuwan</surname><given-names>W.</given-names></name>
<name><surname>Nawaz</surname><given-names>M.</given-names></name>
<name><surname>Pereira</surname><given-names>M.L.</given-names></name>
<name><surname>Hosseini</surname><given-names>S.A.</given-names></name>
<name><surname>Montazeri</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Green synthesis of nano-liposomes containing <italic toggle="yes">Bunium persicum</italic> and <italic toggle="yes">Trachyspermum ammi</italic> essential oils against <italic toggle="yes">Trichomonas vaginalis</italic></article-title><source>J. Microbiol. Immunol. Infect.</source><year>2023</year><volume>56</volume><fpage>150</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1016/j.jmii.2022.06.006</pub-id><pub-id pub-id-type="pmid">35864068</pub-id>
</element-citation></ref><ref id="B57-pharmaceutics-17-00178"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wen</surname><given-names>M.M.</given-names></name>
<name><surname>Abdelwahab</surname><given-names>I.A.</given-names></name>
<name><surname>Aly</surname><given-names>R.G.</given-names></name>
<name><surname>El-Zahaby</surname><given-names>S.A.</given-names></name>
</person-group><article-title>Nanophyto-gel against multi-drug resistant <italic toggle="yes">Pseudomonas aeruginosa</italic> burn wound infection</article-title><source>Drug Deliv.</source><year>2021</year><volume>28</volume><fpage>463</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1080/10717544.2021.1889720</pub-id><pub-id pub-id-type="pmid">33620004</pub-id>
</element-citation></ref><ref id="B58-pharmaceutics-17-00178"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Palmas</surname><given-names>L.</given-names></name>
<name><surname>Aroffu</surname><given-names>M.</given-names></name>
<name><surname>Petretto</surname><given-names>G.L.</given-names></name>
<name><surname>Escribano-Ferrer</surname><given-names>E.</given-names></name>
<name><surname>D&#x000ed;ez-Sales</surname><given-names>O.</given-names></name>
<name><surname>Usach</surname><given-names>I.</given-names></name>
<name><surname>Peris</surname><given-names>J.-E.</given-names></name>
<name><surname>Marongiu</surname><given-names>F.</given-names></name>
<name><surname>Ghavam</surname><given-names>M.</given-names></name>
<name><surname>Fais</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Entrapment of <italic toggle="yes">citrus limon</italic> var. <italic toggle="yes">Pompia</italic> essential oil or pure citral in liposomes tailored as mouthwash for the treatment of oral cavity diseases</article-title><source>Pharmaceuticals</source><year>2020</year><volume>13</volume><elocation-id>216</elocation-id><pub-id pub-id-type="doi">10.3390/ph13090216</pub-id><pub-id pub-id-type="pmid">32872140</pub-id>
</element-citation></ref><ref id="B59-pharmaceutics-17-00178"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maocha</surname><given-names>I.</given-names></name>
<name><surname>Rosado</surname><given-names>B.</given-names></name>
<name><surname>Lopes-Nunes</surname><given-names>J.</given-names></name>
<name><surname>Lopes</surname><given-names>M.</given-names></name>
<name><surname>Rolo</surname><given-names>J.</given-names></name>
<name><surname>Pires</surname><given-names>B.</given-names></name>
<name><surname>Gallardo</surname><given-names>E.</given-names></name>
<name><surname>Palmeira-De-Oliveira</surname><given-names>A.</given-names></name>
<name><surname>Martinez-De-Oliveira</surname><given-names>J.</given-names></name>
<name><surname>de Oliveira</surname><given-names>R.P.</given-names></name>
<etal/>
</person-group><article-title>Imiquimod-Loaded Nanosystem for Treatment Human Papillomavirus-Induced Lesions</article-title><source>Pharmaceutics</source><year>2024</year><volume>16</volume><elocation-id>864</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics16070864</pub-id><pub-id pub-id-type="pmid">39065561</pub-id>
</element-citation></ref><ref id="B60-pharmaceutics-17-00178"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ribeiro</surname><given-names>R.</given-names></name>
<name><surname>Fernandes</surname><given-names>L.</given-names></name>
<name><surname>Costa</surname><given-names>R.</given-names></name>
<name><surname>Cavaleiro</surname><given-names>C.</given-names></name>
<name><surname>Salgueiro</surname><given-names>L.</given-names></name>
<name><surname>Henriques</surname><given-names>M.</given-names></name>
<name><surname>Rodrigues</surname><given-names>M.E.</given-names></name>
</person-group><article-title>Comparing the effect of <italic toggle="yes">Thymus</italic> spp. essential oils on <italic toggle="yes">Candida auris</italic></article-title><source>Ind. Crops Prod.</source><year>2022</year><volume>178</volume><fpage>114667</fpage><pub-id pub-id-type="doi">10.1016/j.indcrop.2022.114667</pub-id></element-citation></ref><ref id="B61-pharmaceutics-17-00178"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kowalczyk</surname><given-names>A.</given-names></name>
</person-group><article-title>Essential Oils against <italic toggle="yes">Candida auris</italic>&#x02014;A Promising Approach for Antifungal Activity</article-title><source>Antibiotics</source><year>2024</year><volume>13</volume><elocation-id>568</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics13060568</pub-id><pub-id pub-id-type="pmid">38927234</pub-id>
</element-citation></ref><ref id="B62-pharmaceutics-17-00178"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Salam</surname><given-names>A.M.A.E.</given-names></name>
<name><surname>Tahoun</surname><given-names>A.</given-names></name>
<name><surname>Hanafy</surname><given-names>N.A.</given-names></name>
</person-group><article-title>Evaluation of liposomal hydrocolloidal NPs loaded by tea tree oil as antifungal agent in vitro and in vivo investigations: Preclinical studies</article-title><source>Food Hydrocoll. Health</source><year>2023</year><volume>3</volume><fpage>100136</fpage><pub-id pub-id-type="doi">10.1016/j.fhfh.2023.100136</pub-id></element-citation></ref><ref id="B63-pharmaceutics-17-00178"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Alteriis</surname><given-names>E.</given-names></name>
<name><surname>Maione</surname><given-names>A.</given-names></name>
<name><surname>Falanga</surname><given-names>A.</given-names></name>
<name><surname>Bellavita</surname><given-names>R.</given-names></name>
<name><surname>Galdiero</surname><given-names>S.</given-names></name>
<name><surname>Albarano</surname><given-names>L.</given-names></name>
<name><surname>Salvatore</surname><given-names>M.M.</given-names></name>
<name><surname>Galdiero</surname><given-names>E.</given-names></name>
<name><surname>Guida</surname><given-names>M.</given-names></name>
</person-group><article-title>Activity of Free and Liposome-Encapsulated Essential Oil from <italic toggle="yes">Lavandula angustifolia</italic> against Persister-Derived Biofilm of <italic toggle="yes">Candida auris</italic></article-title><source>Antibiotics</source><year>2022</year><volume>11</volume><elocation-id>26</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics11010026</pub-id><pub-id pub-id-type="pmid">35052903</pub-id>
</element-citation></ref><ref id="B64-pharmaceutics-17-00178"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baldim</surname><given-names>I.</given-names></name>
<name><surname>Paziani</surname><given-names>M.H.</given-names></name>
<name><surname>Bari&#x000e3;o</surname><given-names>P.H.G.</given-names></name>
<name><surname>von Zeska Kress</surname><given-names>M.R.</given-names></name>
<name><surname>Oliveira</surname><given-names>W.P.</given-names></name>
</person-group><article-title>Nanostructured Lipid Carriers Loaded with <italic toggle="yes">Lippia sidoides</italic> Essential Oil as a Strategy to Combat the Multidrug-Resistant <italic toggle="yes">Candida auris</italic></article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><elocation-id>180</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14010180</pub-id><pub-id pub-id-type="pmid">35057078</pub-id>
</element-citation></ref><ref id="B65-pharmaceutics-17-00178"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hussein</surname><given-names>A.</given-names></name>
<name><surname>Abdel-Mottaleb</surname><given-names>M.M.</given-names></name>
<name><surname>El-Assal</surname><given-names>M.</given-names></name>
<name><surname>Sammour</surname><given-names>O.</given-names></name>
</person-group><article-title>Novel biocompatible essential oil-based lipid nanocapsules with antifungal properties</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2020</year><volume>56</volume><fpage>101605</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2020.101605</pub-id></element-citation></ref><ref id="B66-pharmaceutics-17-00178"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gross</surname><given-names>I.P.</given-names></name>
<name><surname>Lima</surname><given-names>A.L.</given-names></name>
<name><surname>Sousa</surname><given-names>E.C.</given-names></name>
<name><surname>Souza</surname><given-names>M.S.</given-names></name>
<name><surname>Cunha-Filho</surname><given-names>M.</given-names></name>
<name><surname>da Silva</surname><given-names>I.C.R.</given-names></name>
<name><surname>Orsi</surname><given-names>D.C.</given-names></name>
<name><surname>S&#x000e1;-Barreto</surname><given-names>L.L.</given-names></name>
</person-group><article-title>Antimicrobial and acaricide sanitizer tablets produced by wet granulation of spray-dried soap and clove oil-loaded microemulsion</article-title><source>PLoS ONE</source><year>2024</year><volume>19</volume><elocation-id>e0313517</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0313517</pub-id><pub-id pub-id-type="pmid">39527597</pub-id>
</element-citation></ref><ref id="B67-pharmaceutics-17-00178"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Drais</surname><given-names>H.K.</given-names></name>
</person-group><article-title>Development and Evaluation Essential Oils Nanoemulgel as Human Skin Sanitizer Using Novel Method</article-title><source>Turk. J. Pharm. Sci.</source><year>2023</year><volume>21</volume><fpage>456</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.4274/tjps.galenos.2023.78006</pub-id><pub-id pub-id-type="pmid">39569700</pub-id>
</element-citation></ref><ref id="B68-pharmaceutics-17-00178"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mechmechani</surname><given-names>S.</given-names></name>
<name><surname>Khelissa</surname><given-names>S.</given-names></name>
<name><surname>Gharsallaoui</surname><given-names>A.</given-names></name>
<name><surname>Omari</surname><given-names>K.E.</given-names></name>
<name><surname>Hamze</surname><given-names>M.</given-names></name>
<name><surname>Chihib</surname><given-names>N.-E.</given-names></name>
</person-group><article-title>Hurdle technology using encapsulated enzymes and essential oils to fight bacterial biofilms</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2022</year><volume>106</volume><fpage>2311</fpage><lpage>2335</lpage><pub-id pub-id-type="doi">10.1007/s00253-022-11875-5</pub-id><pub-id pub-id-type="pmid">35312826</pub-id>
</element-citation></ref><ref id="B69-pharmaceutics-17-00178"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Unnisa</surname><given-names>A.</given-names></name>
<name><surname>Chettupalli</surname><given-names>A.K.</given-names></name>
<name><surname>Alazragi</surname><given-names>R.S.</given-names></name>
<name><surname>Alelwani</surname><given-names>W.</given-names></name>
<name><surname>Bannunah</surname><given-names>A.M.</given-names></name>
<name><surname>Barnawi</surname><given-names>J.</given-names></name>
<name><surname>Amarachinta</surname><given-names>P.R.</given-names></name>
<name><surname>Jandrajupalli</surname><given-names>S.B.</given-names></name>
<name><surname>Elamine</surname><given-names>B.A.</given-names></name>
<name><surname>Mohamed</surname><given-names>O.A.</given-names></name>
<etal/>
</person-group><article-title>Nanostructured Lipid Carriers to Enhance the Bioavailability and Solubility of Ranolazine: Statistical Optimization and Pharmacological Evaluations</article-title><source>Pharmaceuticals</source><year>2023</year><volume>16</volume><elocation-id>1151</elocation-id><pub-id pub-id-type="doi">10.3390/ph16081151</pub-id><pub-id pub-id-type="pmid">37631066</pub-id>
</element-citation></ref><ref id="B70-pharmaceutics-17-00178"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dumlu</surname><given-names>B.</given-names></name>
</person-group><article-title>Importance of Nano-Sized Feed Additives in Animal Nutrition</article-title><source>J. Agric. Prod.</source><year>2024</year><volume>5</volume><fpage>55</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.56430/japro.1433614</pub-id></element-citation></ref><ref id="B71-pharmaceutics-17-00178"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gelaye</surname><given-names>Y.</given-names></name>
</person-group><article-title>Application of nanotechnology in animal nutrition: Bibliographic review</article-title><source>Cogent Food Agric.</source><year>2024</year><volume>10</volume><fpage>2290308</fpage><pub-id pub-id-type="doi">10.1080/23311932.2023.2290308</pub-id></element-citation></ref><ref id="B72-pharmaceutics-17-00178"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meligy</surname><given-names>A.M.</given-names></name>
<name><surname>El-Hamid</surname><given-names>M.I.A.</given-names></name>
<name><surname>Yonis</surname><given-names>A.E.</given-names></name>
<name><surname>Elhaddad</surname><given-names>G.Y.</given-names></name>
<name><surname>Abdel-Raheem</surname><given-names>S.M.</given-names></name>
<name><surname>El-Ghareeb</surname><given-names>W.R.</given-names></name>
<name><surname>Mohamed</surname><given-names>M.H.</given-names></name>
<name><surname>Ismail</surname><given-names>H.</given-names></name>
<name><surname>Ibrahim</surname><given-names>D.</given-names></name>
</person-group><article-title>Liposomal encapsulated oregano, cinnamon, and clove oils enhanced the performance, bacterial metabolites antioxidant potential, and intestinal microbiota of broiler chickens</article-title><source>Poult. Sci.</source><year>2023</year><volume>102</volume><fpage>102683</fpage><pub-id pub-id-type="doi">10.1016/j.psj.2023.102683</pub-id><pub-id pub-id-type="pmid">37120892</pub-id>
</element-citation></ref><ref id="B73-pharmaceutics-17-00178"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Souza Silveira Valente</surname><given-names>J.</given-names></name>
<name><surname>de Oliveira da Silva Fonseca</surname><given-names>A.</given-names></name>
<name><surname>Brasil</surname><given-names>C.L.</given-names></name>
<name><surname>Sagave</surname><given-names>L.</given-names></name>
<name><surname>Flores</surname><given-names>F.C.</given-names></name>
<name><surname>de Bona da Silva</surname><given-names>C.</given-names></name>
<name><surname>Sangioni</surname><given-names>L.A.</given-names></name>
<name><surname>P&#x000f6;tter</surname><given-names>L.</given-names></name>
<name><surname>Santurio</surname><given-names>J.M.</given-names></name>
<name><surname>de Avila Botton</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>In Vitro Activity of <italic toggle="yes">Melaleuca alternifolia</italic> (Tea Tree) in Its Free Oil and Nanoemulsion Formulations Against <italic toggle="yes">Pythium insidiosum</italic></article-title><source>Mycopathologia</source><year>2016</year><volume>181</volume><fpage>865</fpage><lpage>869</lpage><pub-id pub-id-type="doi">10.1007/s11046-016-0051-2</pub-id><pub-id pub-id-type="pmid">27544535</pub-id>
</element-citation></ref><ref id="B74-pharmaceutics-17-00178"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qadeer</surname><given-names>A.</given-names></name>
<name><surname>Khan</surname><given-names>A.</given-names></name>
<name><surname>Khan</surname><given-names>N.M.</given-names></name>
<name><surname>Wajid</surname><given-names>A.</given-names></name>
<name><surname>Ullah</surname><given-names>K.</given-names></name>
<name><surname>Skalickova</surname><given-names>S.</given-names></name>
<name><surname>Chilala</surname><given-names>P.</given-names></name>
<name><surname>Slama</surname><given-names>P.</given-names></name>
<name><surname>Horky</surname><given-names>P.</given-names></name>
<name><surname>Alqahtani</surname><given-names>M.S.</given-names></name>
<etal/>
</person-group><article-title>Use of nanotechnology-based nanomaterial as a substitute for antibiotics in monogastric animals</article-title><source>Heliyon</source><year>2024</year><volume>10</volume><fpage>e31728</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2024.e31728</pub-id><pub-id pub-id-type="pmid">38845989</pub-id>
</element-citation></ref><ref id="B75-pharmaceutics-17-00178"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Choudhary</surname><given-names>P.</given-names></name>
<name><surname>Bhanjana</surname><given-names>G.</given-names></name>
<name><surname>Kumar</surname><given-names>S.</given-names></name>
<name><surname>Dilbaghi</surname><given-names>N.</given-names></name>
</person-group><article-title>Development and evaluation of eco-friendly carvacrol nanoemulsion as a sustainable biopesticide against bacterial leaf blight of cluster bean</article-title><source>Pest. Manag. Sci.</source><year>2024</year><volume>80</volume><fpage>452</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1002/ps.7776</pub-id><pub-id pub-id-type="pmid">37721471</pub-id>
</element-citation></ref><ref id="B76-pharmaceutics-17-00178"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaur</surname><given-names>R.</given-names></name>
<name><surname>Choudhary</surname><given-names>D.</given-names></name>
<name><surname>Bali</surname><given-names>S.</given-names></name>
<name><surname>Bandral</surname><given-names>S.S.</given-names></name>
<name><surname>Singh</surname><given-names>V.</given-names></name>
<name><surname>Ahmad</surname><given-names>A.</given-names></name>
<name><surname>Rani</surname><given-names>N.</given-names></name>
<name><surname>Singh</surname><given-names>T.G.</given-names></name>
<name><surname>Chandrasekaran</surname><given-names>B.</given-names></name>
</person-group><article-title>Pesticides: An alarming detrimental to health and environment</article-title><source>Sci. Total Environ.</source><year>2024</year><volume>915</volume><fpage>170113</fpage><pub-id pub-id-type="doi">10.1016/j.scitotenv.2024.170113</pub-id><pub-id pub-id-type="pmid">38232846</pub-id>
</element-citation></ref><ref id="B77-pharmaceutics-17-00178"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Luker</surname><given-names>H.A.</given-names></name>
<name><surname>Salas</surname><given-names>K.R.</given-names></name>
<name><surname>Esmaeili</surname><given-names>D.</given-names></name>
<name><surname>Holguin</surname><given-names>F.O.</given-names></name>
<name><surname>Bendzus-Mendoza</surname><given-names>H.</given-names></name>
<name><surname>Hansen</surname><given-names>I.A.</given-names></name>
</person-group><article-title>Repellent efficacy of 20 essential oils on <italic toggle="yes">Aedes aegypti</italic> mosquitoes and Ixodes scapularis ticks in contact-repellency assays</article-title><source>Sci. Rep.</source><year>2023</year><volume>13</volume><elocation-id>1705</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-023-28820-9</pub-id><pub-id pub-id-type="pmid">36717735</pub-id>
</element-citation></ref><ref id="B78-pharmaceutics-17-00178"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pereira</surname><given-names>P.C.</given-names></name>
<name><surname>Parente</surname><given-names>C.E.</given-names></name>
<name><surname>Carvalho</surname><given-names>G.O.</given-names></name>
<name><surname>Torres</surname><given-names>J.P.</given-names></name>
<name><surname>Meire</surname><given-names>R.O.</given-names></name>
<name><surname>Dorneles</surname><given-names>P.R.</given-names></name>
<name><surname>Malm</surname><given-names>O.</given-names></name>
</person-group><article-title>A review on pesticides in flower production: A push to reduce human exposure and environmental contamination</article-title><source>Environ. Pollut.</source><year>2021</year><volume>289</volume><fpage>117817</fpage><pub-id pub-id-type="doi">10.1016/j.envpol.2021.117817</pub-id><pub-id pub-id-type="pmid">34333268</pub-id>
</element-citation></ref><ref id="B79-pharmaceutics-17-00178"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pathak</surname><given-names>A.</given-names></name>
<name><surname>Mandal</surname><given-names>N.</given-names></name>
<name><surname>Upadhyaya</surname><given-names>D.C.</given-names></name>
<name><surname>Joshi</surname><given-names>N.</given-names></name>
<name><surname>Upadhyaya</surname><given-names>C.P.</given-names></name>
</person-group><article-title>Lipid nanoparticles: A sustainable solution for crop disease management</article-title><source>Adv. Nat. Sci. Nanosci. Nanotechnol.</source><year>2024</year><volume>15</volume><fpage>033001</fpage><pub-id pub-id-type="doi">10.1088/2043-6262/ad6cbe</pub-id></element-citation></ref><ref id="B80-pharmaceutics-17-00178"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hikal</surname><given-names>W.M.</given-names></name>
<name><surname>Baz</surname><given-names>M.M.</given-names></name>
<name><surname>Alshehri</surname><given-names>M.A.</given-names></name>
<name><surname>Bahattab</surname><given-names>O.</given-names></name>
<name><surname>Baeshen</surname><given-names>R.S.</given-names></name>
<name><surname>Selim</surname><given-names>A.M.</given-names></name>
<name><surname>Alhwity</surname><given-names>L.</given-names></name>
<name><surname>Bousbih</surname><given-names>R.</given-names></name>
<name><surname>Alshourbaji</surname><given-names>M.S.</given-names></name>
<name><surname>Ahl</surname><given-names>H.A.H.S.-A.</given-names></name>
</person-group><article-title>Sustainable Pest Management Using Novel Nanoemulsions of Honeysuckle and Patchouli Essential Oils against the West Nile Virus Vector, <italic toggle="yes">Culex pipiens</italic>, under Laboratory and Field Conditions</article-title><source>Plants</source><year>2023</year><volume>12</volume><elocation-id>3682</elocation-id><pub-id pub-id-type="doi">10.3390/plants12213682</pub-id><pub-id pub-id-type="pmid">37960039</pub-id>
</element-citation></ref><ref id="B81-pharmaceutics-17-00178"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rodrigues</surname><given-names>A.B.L.</given-names></name>
<name><surname>Martins</surname><given-names>R.L.</given-names></name>
<name><surname>de Menezes Rabelo</surname><given-names>&#x000c9;.</given-names></name>
<name><surname>Tomazi</surname><given-names>R.</given-names></name>
<name><surname>Santos</surname><given-names>L.L.</given-names></name>
<name><surname>Brand&#x000e3;o</surname><given-names>L.B.</given-names></name>
<name><surname>Faustino</surname><given-names>C.G.</given-names></name>
<name><surname>Farias</surname><given-names>A.L.F.</given-names></name>
<name><surname>dos Santos</surname><given-names>C.B.R.</given-names></name>
<name><surname>de Castro Cantu&#x000e1;ria</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Development of nano-emulsions based on <italic toggle="yes">Ayapana triplinervis</italic> essential oil for the control of <italic toggle="yes">Aedes aegypti</italic> larvae</article-title><source>PLoS ONE</source><year>2021</year><volume>16</volume><elocation-id>e0254225</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0254225</pub-id><pub-id pub-id-type="pmid">34242328</pub-id>
</element-citation></ref><ref id="B82-pharmaceutics-17-00178"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abdel-Ghany</surname><given-names>H.S.M.</given-names></name>
<name><surname>Abdel-Shafy</surname><given-names>S.</given-names></name>
<name><surname>Abuowarda</surname><given-names>M.</given-names></name>
<name><surname>El-Khateeb</surname><given-names>R.M.</given-names></name>
<name><surname>Hoballah</surname><given-names>E.M.</given-names></name>
<name><surname>Fahmy</surname><given-names>M.M.</given-names></name>
</person-group><article-title>Acaricidal activity of <italic toggle="yes">Artemisia herba-alba</italic> and <italic toggle="yes">Melia azedarach</italic> oil nanoemulsion against <italic toggle="yes">Hyalomma dromedarii</italic> and their toxicity on Swiss albino mice</article-title><source>Exp. Appl. Acarol.</source><year>2021</year><volume>84</volume><fpage>241</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1007/s10493-021-00618-2</pub-id><pub-id pub-id-type="pmid">33934282</pub-id>
</element-citation></ref><ref id="B83-pharmaceutics-17-00178"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Palermo</surname><given-names>D.</given-names></name>
<name><surname>Giunti</surname><given-names>G.</given-names></name>
<name><surname>Laudani</surname><given-names>F.</given-names></name>
<name><surname>Palmeri</surname><given-names>V.</given-names></name>
<name><surname>Campolo</surname><given-names>O.</given-names></name>
</person-group><article-title>Essential oil-based nano-biopesticides: Formulation and bioactivity against the confused flour beetle <italic toggle="yes">tribolium confusum</italic></article-title><source>Sustainability</source><year>2021</year><volume>13</volume><elocation-id>9746</elocation-id><pub-id pub-id-type="doi">10.3390/su13179746</pub-id></element-citation></ref><ref id="B84-pharmaceutics-17-00178"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dunan</surname><given-names>L.</given-names></name>
<name><surname>Malanga</surname><given-names>T.</given-names></name>
<name><surname>Benhamou</surname><given-names>S.</given-names></name>
<name><surname>Papaiconomou</surname><given-names>N.</given-names></name>
<name><surname>Desneux</surname><given-names>N.</given-names></name>
<name><surname>Lavoir</surname><given-names>A.-V.</given-names></name>
<name><surname>Michel</surname><given-names>T.</given-names></name>
</person-group><article-title>Effects of essential oil-based formulation on biopesticide activity</article-title><source>Ind. Crops Prod.</source><year>2023</year><volume>202</volume><fpage>117006</fpage><pub-id pub-id-type="doi">10.1016/j.indcrop.2023.117006</pub-id></element-citation></ref><ref id="B85-pharmaceutics-17-00178"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Manjesh</surname><given-names>K.</given-names></name>
<name><surname>Kundu</surname><given-names>A.</given-names></name>
<name><surname>Dutta</surname><given-names>A.</given-names></name>
<name><surname>Saha</surname><given-names>S.</given-names></name>
<name><surname>Neelakanthaiah</surname><given-names>B.S.</given-names></name>
</person-group><article-title>Bio-Insecticidal Nanoemulsions of Essential Oil and Lipid-Soluble Fractions of <italic toggle="yes">Pogostemon cablin</italic></article-title><source>Front. Plant Sci.</source><year>2022</year><volume>13</volume><elocation-id>874221</elocation-id><pub-id pub-id-type="doi">10.3389/fpls.2022.874221</pub-id><pub-id pub-id-type="pmid">35574070</pub-id>
</element-citation></ref><ref id="B86-pharmaceutics-17-00178"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Teng</surname><given-names>Q.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Cai</surname><given-names>Y.</given-names></name>
<name><surname>Guo</surname><given-names>J.</given-names></name>
<name><surname>Zou</surname><given-names>M.</given-names></name>
<name><surname>Xue</surname><given-names>Q.</given-names></name>
<name><surname>Tang</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Zhao</surname><given-names>J.</given-names></name>
</person-group><article-title>A potential acaricide of <italic toggle="yes">Moutan cortex</italic> essential oil encapsulated in nanoemulsion and mesoporous silica nanoparticles against the house dust mite <italic toggle="yes">Dermatophagoides farinae</italic></article-title><source>J. Pest Sci.</source><year>2024</year><pub-id pub-id-type="doi">10.1007/s10340-024-01820-y</pub-id></element-citation></ref><ref id="B87-pharmaceutics-17-00178"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barbhuiya</surname><given-names>R.I.</given-names></name>
<name><surname>Wroblewski</surname><given-names>C.</given-names></name>
<name><surname>Elsayed</surname><given-names>A.</given-names></name>
<name><surname>Subramanian</surname><given-names>J.</given-names></name>
<name><surname>Kaur</surname><given-names>G.</given-names></name>
<name><surname>Routray</surname><given-names>W.</given-names></name>
<name><surname>Singh</surname><given-names>A.</given-names></name>
</person-group><article-title>Development and physicochemical characterization of <italic toggle="yes">Azadirachta indica</italic> seed oil loaded niosomes nanoparticles: A potential natural pesticide</article-title><source>Chem. Eng. Res. Des.</source><year>2024</year><volume>203</volume><fpage>197</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1016/j.cherd.2024.01.047</pub-id></element-citation></ref><ref id="B88-pharmaceutics-17-00178"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Adamu</surname><given-names>A.</given-names></name>
<name><surname>Ahmad</surname><given-names>K.</given-names></name>
<name><surname>Siddiqui</surname><given-names>Y.</given-names></name>
<name><surname>Ismail</surname><given-names>I.S.</given-names></name>
<name><surname>Asib</surname><given-names>N.</given-names></name>
<name><surname>Bashir Kutawa</surname><given-names>A.</given-names></name>
<name><surname>Adzmi</surname><given-names>F.</given-names></name>
<name><surname>Ismail</surname><given-names>M.R.</given-names></name>
<name><surname>Berahim</surname><given-names>Z.</given-names></name>
</person-group><article-title>Ginger essential oils-loaded nanoemulsions: Potential strategy to manage bacterial leaf blight disease and enhanced rice yield</article-title><source>Molecules</source><year>2021</year><volume>26</volume><elocation-id>3902</elocation-id><pub-id pub-id-type="doi">10.3390/molecules26133902</pub-id><pub-id pub-id-type="pmid">34202405</pub-id>
</element-citation></ref><ref id="B89-pharmaceutics-17-00178"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tortorici</surname><given-names>S.</given-names></name>
<name><surname>Cimino</surname><given-names>C.</given-names></name>
<name><surname>Ricupero</surname><given-names>M.</given-names></name>
<name><surname>Musumeci</surname><given-names>T.</given-names></name>
<name><surname>Biondi</surname><given-names>A.</given-names></name>
<name><surname>Siscaro</surname><given-names>G.</given-names></name>
<name><surname>Carbone</surname><given-names>C.</given-names></name>
<name><surname>Zappal&#x000e0;</surname><given-names>L.</given-names></name>
</person-group><article-title>Nanostructured lipid carriers of essential oils as potential tools for the sustainable control of insect pests</article-title><source>Ind. Crops Prod.</source><year>2022</year><volume>181</volume><fpage>114766</fpage><pub-id pub-id-type="doi">10.1016/j.indcrop.2022.114766</pub-id></element-citation></ref><ref id="B90-pharmaceutics-17-00178"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Almeida</surname><given-names>L.F.</given-names></name>
<name><surname>Gil</surname><given-names>G.A.</given-names></name>
<name><surname>Moraes</surname><given-names>L.N.</given-names></name>
<name><surname>Furtado</surname><given-names>F.B.</given-names></name>
<name><surname>Kakuda</surname><given-names>L.</given-names></name>
<name><surname>Grotto</surname><given-names>R.M.T.</given-names></name>
<name><surname>Oliveira</surname><given-names>W.P.</given-names></name>
</person-group><article-title>Nanostructured lipid carriers loaded with essential oils: A strategy against SARS-CoV-2</article-title><source>J. Microencapsul.</source><year>2024</year><volume>41</volume><fpage>284</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1080/02652048.2024.2348463</pub-id><pub-id pub-id-type="pmid">38686964</pub-id>
</element-citation></ref><ref id="B91-pharmaceutics-17-00178"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shehabeldine</surname><given-names>A.M.</given-names></name>
<name><surname>Doghish</surname><given-names>A.S.</given-names></name>
<name><surname>El-Dakroury</surname><given-names>W.A.</given-names></name>
<name><surname>Hassanin</surname><given-names>M.M.H.</given-names></name>
<name><surname>Al-Askar</surname><given-names>A.A.</given-names></name>
<name><surname>AbdElgawad</surname><given-names>H.</given-names></name>
<name><surname>Hashem</surname><given-names>A.H.</given-names></name>
</person-group><article-title>Antimicrobial, Antibiofilm, and Anticancer Activities of <italic toggle="yes">Syzygium aromaticum</italic> Essential Oil Nanoemulsion</article-title><source>Molecules</source><year>2023</year><volume>28</volume><elocation-id>5812</elocation-id><pub-id pub-id-type="doi">10.3390/molecules28155812</pub-id><pub-id pub-id-type="pmid">37570781</pub-id>
</element-citation></ref><ref id="B92-pharmaceutics-17-00178"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ekrami</surname><given-names>A.</given-names></name>
<name><surname>Ghadermazi</surname><given-names>M.</given-names></name>
<name><surname>Ekrami</surname><given-names>M.</given-names></name>
<name><surname>Hosseini</surname><given-names>M.A.</given-names></name>
<name><surname>Emam-Djomeh</surname><given-names>Z.</given-names></name>
<name><surname>Hamidi-Moghadam</surname><given-names>R.</given-names></name>
</person-group><article-title>Development and evaluation of <italic toggle="yes">Zhumeria majdae</italic> essential oil-loaded nanoliposome against multidrug-resistant clinical pathogens causing nosocomial infection</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2022</year><volume>69</volume><fpage>103148</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2022.103148</pub-id></element-citation></ref><ref id="B93-pharmaceutics-17-00178"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tazehjani</surname><given-names>D.A.J.</given-names></name>
<name><surname>Farahpour</surname><given-names>M.R.</given-names></name>
<name><surname>Hamishehkar</surname><given-names>H.</given-names></name>
</person-group><article-title>Effectiveness of topical caraway essential oil loaded into nanostructured lipid carrier as a promising platform for the treatment of infected wounds</article-title><source>Colloids Surf. A Physicochem. Eng. Asp.</source><year>2021</year><volume>610</volume><fpage>125748</fpage><pub-id pub-id-type="doi">10.1016/j.colsurfa.2020.125748</pub-id></element-citation></ref><ref id="B94-pharmaceutics-17-00178"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aguilar-P&#x000e9;rez</surname><given-names>K.M.</given-names></name>
<name><surname>Medina</surname><given-names>D.I.</given-names></name>
<name><surname>Narayanan</surname><given-names>J.</given-names></name>
<name><surname>Parra-Sald&#x000ed;var</surname><given-names>R.</given-names></name>
<name><surname>Iqbal</surname><given-names>H.M.N.</given-names></name>
</person-group><article-title>Synthesis and nano-sized characterization of bioactive oregano essential oil molecule-loaded small unilamellar nanoliposomes with antifungal potentialities</article-title><source>Molecules</source><year>2021</year><volume>26</volume><elocation-id>2880</elocation-id><pub-id pub-id-type="doi">10.3390/molecules26102880</pub-id><pub-id pub-id-type="pmid">34068039</pub-id>
</element-citation></ref><ref id="B95-pharmaceutics-17-00178"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Usach</surname><given-names>I.</given-names></name>
<name><surname>Margarucci</surname><given-names>E.</given-names></name>
<name><surname>Manca</surname><given-names>M.L.</given-names></name>
<name><surname>Caddeo</surname><given-names>C.</given-names></name>
<name><surname>Aroffu</surname><given-names>M.</given-names></name>
<name><surname>Petretto</surname><given-names>G.L.</given-names></name>
<name><surname>Manconi</surname><given-names>M.</given-names></name>
<name><surname>Peris</surname><given-names>J.-E.</given-names></name>
</person-group><article-title>Comparison between citral and pompia essential oil loaded in phospholipid vesicles for the treatment of skin and mucosal infections</article-title><source>Nanomaterials</source><year>2020</year><volume>10</volume><elocation-id>286</elocation-id><pub-id pub-id-type="doi">10.3390/nano10020286</pub-id><pub-id pub-id-type="pmid">32046201</pub-id>
</element-citation></ref><ref id="B96-pharmaceutics-17-00178"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khezri</surname><given-names>K.</given-names></name>
<name><surname>Farahpour</surname><given-names>M.R.</given-names></name>
<name><surname>Mounesi Rad</surname><given-names>S.</given-names></name>
</person-group><article-title>Efficacy of <italic toggle="yes">Mentha pulegium</italic> essential oil encapsulated into nanostructured lipid carriers as an in vitro antibacterial and infected wound healing agent</article-title><source>Colloids Surf. A Physicochem. Eng. Asp.</source><year>2020</year><volume>589</volume><fpage>124414</fpage><pub-id pub-id-type="doi">10.1016/j.colsurfa.2020.124414</pub-id></element-citation></ref><ref id="B97-pharmaceutics-17-00178"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hamedi</surname><given-names>H.</given-names></name>
<name><surname>Moradi</surname><given-names>S.</given-names></name>
<name><surname>Tonelli</surname><given-names>A.E.</given-names></name>
<name><surname>Hudson</surname><given-names>S.M.</given-names></name>
</person-group><article-title>Preparation and characterization of chitosan&#x02013;Alginate polyelectrolyte complexes loaded with antibacterial thyme oil nanoemulsions</article-title><source>Appl. Sci.</source><year>2019</year><volume>9</volume><elocation-id>3933</elocation-id><pub-id pub-id-type="doi">10.3390/app9183933</pub-id></element-citation></ref><ref id="B98-pharmaceutics-17-00178"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghodrati</surname><given-names>M.</given-names></name>
<name><surname>Farahpour</surname><given-names>M.R.</given-names></name>
<name><surname>Hamishehkar</surname><given-names>H.</given-names></name>
</person-group><article-title>Encapsulation of Peppermint essential oil in nanostructured lipid carriers: In-vitro antibacterial activity and accelerative effect on infected wound healing</article-title><source>Colloids Surf. A Physicochem. Eng. Asp.</source><year>2019</year><volume>564</volume><fpage>161</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfa.2018.12.043</pub-id></element-citation></ref><ref id="B99-pharmaceutics-17-00178"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carbone</surname><given-names>C.</given-names></name>
<name><surname>Teixeira</surname><given-names>M.D.C.</given-names></name>
<name><surname>Sousa</surname><given-names>M.D.C.</given-names></name>
<name><surname>Martins-Gomes</surname><given-names>C.</given-names></name>
<name><surname>Silva</surname><given-names>A.M.</given-names></name>
<name><surname>Souto</surname><given-names>E.M.B.</given-names></name>
<name><surname>Musumeci</surname><given-names>T.</given-names></name>
</person-group><article-title>Clotrimazole-loaded mediterranean essential oils NLC: A synergic treatment of <italic toggle="yes">Candida</italic> skin infections</article-title><source>Pharmaceutics</source><year>2019</year><volume>11</volume><elocation-id>231</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics11050231</pub-id><pub-id pub-id-type="pmid">31085997</pub-id>
</element-citation></ref><ref id="B100-pharmaceutics-17-00178"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meghani</surname><given-names>N.</given-names></name>
<name><surname>Mansuri</surname><given-names>A.</given-names></name>
<name><surname>Chaudhari</surname><given-names>R.</given-names></name>
<name><surname>Kumar</surname><given-names>A.</given-names></name>
</person-group><article-title>Fabrication, assessment, and potential anti-bacterial activity of sandalwood oil nanoemulsion and its hand rub sanitizer</article-title><source>Environ. Sci. Pollut. Res.</source><year>2024</year><volume>31</volume><fpage>46546</fpage><lpage>46557</lpage><pub-id pub-id-type="doi">10.1007/s11356-023-26945-y</pub-id></element-citation></ref><ref id="B101-pharmaceutics-17-00178"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mehta</surname><given-names>M.</given-names></name>
<name><surname>Bui</surname><given-names>T.A.</given-names></name>
<name><surname>Yang</surname><given-names>X.</given-names></name>
<name><surname>Aksoy</surname><given-names>Y.</given-names></name>
<name><surname>Goldys</surname><given-names>E.M.</given-names></name>
<name><surname>Deng</surname><given-names>W.</given-names></name>
</person-group><article-title>Lipid-Based Nanoparticles for Drug/Gene Delivery: An Overview of the Production Techniques and Difficulties Encountered in Their Industrial Development</article-title><source>ACS Mater. Au</source><year>2023</year><volume>3</volume><fpage>600</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1021/acsmaterialsau.3c00032</pub-id><pub-id pub-id-type="pmid">38089666</pub-id>
</element-citation></ref><ref id="B102-pharmaceutics-17-00178"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Biscaia-Caleiras</surname><given-names>M.</given-names></name>
<name><surname>Fonseca</surname><given-names>N.A.</given-names></name>
<name><surname>Louren&#x000e7;o</surname><given-names>A.S.</given-names></name>
<name><surname>Moreira</surname><given-names>J.N.</given-names></name>
<name><surname>Sim&#x000f5;es</surname><given-names>S.</given-names></name>
</person-group><article-title>Rational formulation and industrial manufacturing of lipid-based complex injectables: Landmarks and trends</article-title><source>J. Control. Release</source><year>2024</year><volume>373</volume><fpage>617</fpage><lpage>639</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2024.07.021</pub-id><pub-id pub-id-type="pmid">39002799</pub-id>
</element-citation></ref><ref id="B103-pharmaceutics-17-00178"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eugster</surname><given-names>R.</given-names></name>
<name><surname>Orsi</surname><given-names>M.</given-names></name>
<name><surname>Buttitta</surname><given-names>G.</given-names></name>
<name><surname>Serafini</surname><given-names>N.</given-names></name>
<name><surname>Tiboni</surname><given-names>M.</given-names></name>
<name><surname>Casettari</surname><given-names>L.</given-names></name>
<name><surname>Reymond</surname><given-names>J.-L.</given-names></name>
<name><surname>Aleandri</surname><given-names>S.</given-names></name>
<name><surname>Luciani</surname><given-names>P.</given-names></name>
</person-group><article-title>Leveraging machine learning to streamline the development of liposomal drug delivery systems</article-title><source>J. Control. Release</source><year>2024</year><volume>376</volume><fpage>1025</fpage><lpage>1038</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2024.10.065</pub-id><pub-id pub-id-type="pmid">39489466</pub-id>
</element-citation></ref><ref id="B104-pharmaceutics-17-00178"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bezelya</surname><given-names>A.</given-names></name>
<name><surname>K&#x000fc;&#x000e7;&#x000fc;kt&#x000fc;rkmen</surname><given-names>B.</given-names></name>
<name><surname>Bozk&#x00131;r</surname><given-names>A.</given-names></name>
</person-group><article-title>Microfluidic Devices for Precision Nanoparticle Production</article-title><source>Micro</source><year>2023</year><volume>3</volume><fpage>822</fpage><lpage>866</lpage><pub-id pub-id-type="doi">10.3390/micro3040058</pub-id></element-citation></ref><ref id="B105-pharmaceutics-17-00178"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Javed</surname><given-names>S.</given-names></name>
<name><surname>Mangla</surname><given-names>B.</given-names></name>
<name><surname>Salawi</surname><given-names>A.</given-names></name>
<name><surname>Sultan</surname><given-names>M.H.</given-names></name>
<name><surname>Almoshari</surname><given-names>Y.</given-names></name>
<name><surname>Ahsan</surname><given-names>W.</given-names></name>
</person-group><article-title>Essential Oils as Dermocosmetic Agents, Their Mechanism of Action and Nanolipidic Formulations for Maximized Skincare</article-title><source>Cosmetics</source><year>2024</year><volume>11</volume><elocation-id>210</elocation-id><pub-id pub-id-type="doi">10.3390/cosmetics11060210</pub-id></element-citation></ref><ref id="B106-pharmaceutics-17-00178"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chemat</surname><given-names>F.</given-names></name>
<name><surname>Abert-Vian</surname><given-names>M.</given-names></name>
<name><surname>Fabiano-Tixier</surname><given-names>A.S.</given-names></name>
<name><surname>Strube</surname><given-names>J.</given-names></name>
<name><surname>Uhlenbrock</surname><given-names>L.</given-names></name>
<name><surname>Gunjevic</surname><given-names>V.</given-names></name>
<name><surname>Cravotto</surname><given-names>G.</given-names></name>
</person-group><article-title>Green extraction of natural products. Origins, current status, and future challenges</article-title><source>TrAC Trends Anal. Chem.</source><year>2019</year><volume>118</volume><fpage>248</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1016/j.trac.2019.05.037</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap position="float" id="pharmaceutics-17-00178-t001"><object-id pub-id-type="pii">pharmaceutics-17-00178-t001_Table 1</object-id><label>Table 1</label><caption><p>Lipid nanoparticles loaded with different essential oils with antimicrobial activity and their uses in the human/animal health and environmental fields.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">LNP</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">System Composition</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">EO Loaded</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">EE (%)</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Stability Data</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Target</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Biological Tests</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Results</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Reference</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Size (nm)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Storage <break/>Temperature</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Storage Time (days)</th></tr></thead><tbody><tr><td colspan="11" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Human Applications</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LUV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1,2-distearoyl-sn-glycero-3-phosphocholine, <sc>l</sc>-&#x003b1;-phosphatidylcholine from egg yolk, curcumin and EO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Lippia </italic>
<break/>
<italic toggle="yes">origanoides</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">110.0&#x02013;115.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 &#x000b0;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Staphylococcus aureus</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro antimicrobial activity and assessment of cytotoxic activity in vitro.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LUV composed by L-&#x003b1;-phosphatidylcholine and 600 &#x003bc;g/mL of EO and curcumin inhibited bacterial growth by approximately 65%, which showed statistically significant differences compared with the control. No cytotoxicity toward VERO cells was observed.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B37-pharmaceutics-17-00178" ref-type="bibr">37</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiple lipid nanoparticles</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glyceryl trioleate, glyceryl tristearate, Pluronic<sup>&#x000ae;</sup> L64, Tween<sup>&#x000ae;</sup> 80 and EO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rosemary</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31.0&#x02013;51.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~110.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 &#x000b0;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Pseudomonas aeruginosa</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial susceptibility test by MIC.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Considerable increase in the antibacterial property of EO-loaded lipid nanoparticles.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B38-pharmaceutics-17-00178" ref-type="bibr">38</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SLN gel</td><td align="center" valign="middle" rowspan="1" colspan="1">Tween<sup>&#x000ae;</sup> 80, soya lecithin, cholesterol, dichloromethane, Carbomer&#x000ae; 940, EO, propylene glycol and triethanolamine</td><td align="center" valign="middle" rowspan="1" colspan="1">Lavender</td><td align="center" valign="middle" rowspan="1" colspan="1">75.4</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;20.0</td><td align="center" valign="middle" rowspan="1" colspan="1">25 &#x000b0;C</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Staphylococcus aureus</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Antibacterial assay (MIC, MBC, disk diffusion method) and cell compatibility assay.</td><td align="center" valign="middle" rowspan="1" colspan="1">The SLN potentiated the antibacterial properties of the EO. The incorporation of SLN in the gel matrix enhanced the sustained delivery of the EO. No toxic effects were observed.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B40-pharmaceutics-17-00178" ref-type="bibr">40</xref>]</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">NIO </td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Tween<sup>&#x000ae;</sup> 80, cholesterol, distearoyl phosphoethanolamine-polyethylene glycol, EO</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Bunium persicum</italic>
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">63.1 </td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">159.7 </td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">4 &#x000b0;C</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">120</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Trichomonas vaginalis</italic>
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cytotoxicity tests with human foreskin fibroblasts cell line and in vitro activity against <italic toggle="yes">T. vaginalis</italic>.</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Low cytotoxicity of NIO on healthy cells and high toxicity on <italic toggle="yes">T. vaginalis</italic> parasite.</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B41-pharmaceutics-17-00178" ref-type="bibr">41</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">LNP</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">System Composition</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">EO Loaded</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">EE (%)</td><td colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Stability Data</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Target</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Biological Tests</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Results</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reference</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Size (nm)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Storage <break/>Temperature</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Storage Time (days)</td></tr><tr><td colspan="11" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Human Applications</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NLC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glycerin monostearate, caprylic acid/capric triglyceride, poloxamer 188, egg yolk lecithin and EO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Artemisia argyi</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 &#x000b0;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatitis B <break/>virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-HBV activity in vitro and in vivo and acute toxicity in vivo.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EO-loaded NLC displayed potent in vitro and in vivo anti-HBV activity with improved oral bioavailability and liver exposure.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B42-pharmaceutics-17-00178" ref-type="bibr">42</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NLC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ucuuba butter, poloxamer 188 and essential oil</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Cynnamomum zeylanicum</italic>, <italic toggle="yes">Origanum vulgare</italic>, <italic toggle="yes">Melaleuca artenifolia</italic> and <italic toggle="yes">Mentha pipperita</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;300</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 &#x000b0;C, with thermal cycling stability at 40 &#x000b0;C and 15 &#x000b0;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">365</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">A. baumannii</italic>, <italic toggle="yes">P. aeruginosa, K. pneumoniae</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro antibacterial activity (MIC) and in vivo nanotoxicity assay on a chicken embryo model.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NLC demonstrated long-term stability and showed antibacterial activity. The cinnamon-EO-based NLC was the most efficient system at inhibiting bacterial growth, and was safe under all conditions tested in nanotoxicity test.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B43-pharmaceutics-17-00178" ref-type="bibr">43</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NLC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Beeswax, Poloxamer 188, chitosan and <italic toggle="yes">Citrus sinensi</italic> OE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Citrus sinensi</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">103.6 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 and 25 &#x000b0;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Leishmania infantum</italic> and <italic toggle="yes">Leishmania amazonensis</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Leishmanicidal activity and in vitro cytotoxicity in L929 and RAW 264.7 cells.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NLC significantly reduced the viability of promastigote forms of <italic toggle="yes">L. amazonensis</italic>. Chitosan-coated NLC provided better antileishmanial activity than uncoated NLC.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B54-pharmaceutics-17-00178" ref-type="bibr">54</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tween<sup>&#x000ae;</sup> 20 and cinnamon EO (0.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Cinnamomum zeylanicum</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 and 25 &#x000b0;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">180</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Leishmania major</italic> and <italic toggle="yes">Leishmania tropica</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Leishmanicidal activity assay in vitro.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NE improved the anti-leishmania activity.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B55-pharmaceutics-17-00178" ref-type="bibr">55</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">LNP</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">System Composition</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">EO Loaded</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">EE (%)</td><td colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Stability Data</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Target</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Biological Tests</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Results</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reference</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Size (nm)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Storage <break/>Temperature</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Storage Time (days)</td></tr><tr><td colspan="11" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Human Applications</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LUV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Soybean phosphatidylcholine, cholesterol and EO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Bunium persicum</italic> and <italic toggle="yes">Trachyspermum ammi</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51.64 and 40.12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02264;121.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Trichomonas vaginalis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytotoxicity studies (MTT assay), cellular uptake study and determination of IC<sub>50</sub> LUV on <italic toggle="yes">T. vaginalis</italic>.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cellular studies showed that the LUV had a low toxicity for healthy cells but showed toxicity to <italic toggle="yes">T. vaginalis.</italic> The LUV were well absorbed by the cells. The IC<sub>50</sub> values of the LUV composed of <italic toggle="yes">B. persicum</italic> and <italic toggle="yes">T. ammi</italic> were calculated to be 14.41 and 8.08 &#x003bc;g/mL in <italic toggle="yes">T. vaginalis</italic> after 24 h, respectively.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B56-pharmaceutics-17-00178" ref-type="bibr">56</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NLC gel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tween<sup>&#x000ae;</sup> 80, Poloxamer 407, Labrafac&#x02122; lipophile WL 1349, stearic acid and EO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Cinnamomum zeylanicum</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 &#x000b0;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Pseudomonas aeruginosa</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Determination of MIC, in vivo burnt wound study and histological examination.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gel containing NLC effectively entrapped the cinnamon EO, significantly improved wound healing and exhibited an antimicrobial effect.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B57-pharmaceutics-17-00178" ref-type="bibr">57</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LUV hybrid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cholesterol, phospholipid, chitosan and <italic toggle="yes">tea tree</italic> EO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Tea tree</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">360.0&#x02013;420.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;20 &#x000b0;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Aspergillus flavus</italic>, <italic toggle="yes">Aspergillus fumigatus</italic>, <italic toggle="yes">Fusarium oxysporum</italic> and <italic toggle="yes">Microsporum gypsum</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antifungal in vitro assay (MIC, MFC), cytotoxicity study and in vivo antifungal activity analyses in a rat model.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hybrid LUV showed MIC and MFC values that ranged between 0.039 and 1.25 and 0.0195 and 0.625 mg/mL, respectively. A study of the cytotoxicity on liver cells recorded safety levels at a concentration of 5 mg/mL. In vivo assays revealed formulation antifungal activity without causing any noticeable toxicity.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B62-pharmaceutics-17-00178" ref-type="bibr">62</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">LNP</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">System Composition</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">EO Loaded</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">EE (%)</td><td colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Stability Data</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Target</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Biological Tests</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Results</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reference</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Size (nm)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Storage <break/>Temperature</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Storage Time (days)</td></tr><tr><td colspan="11" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Human Applications</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LUV</td><td align="center" valign="middle" rowspan="1" colspan="1"><sc>l</sc>-&#x003b1;-phosphatidylcholine, cholesterol and <italic toggle="yes">L. angustifolia</italic> EO</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Lavandula angustifolia</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">100.0</td><td align="center" valign="middle" rowspan="1" colspan="1">177.2</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Candida auris</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Antifungal activity on planktonic cells and biofilms of <italic toggle="yes">C. auris.</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">Significative growth reduction was observed on planktonic fungi when the cells were incubated in the presence of LUV in an EO concentration of 0.01% <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>. The eradication of biofilms was obtained at higher concentrations of EO (0.5% <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>).</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B63-pharmaceutics-17-00178" ref-type="bibr">63</xref>]</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">NLC</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compritol<sup>&#x000ae;</sup> 888 ATO, Carnauba wax and Beeswax, oleic acid, sodium dodecyl sulfate and <italic toggle="yes">L. sidoides</italic> EO (1.8 % <italic toggle="yes">w</italic>/<italic toggle="yes">w)</italic></td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Lippia sidoides</italic>
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">90&#x02013;100</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">213.1&#x02013;445.5</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">25 &#x000b0;C</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Candida auris</italic>
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antifungal activity (MIC and MFC) and in vivo toxicity assay.</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Candida auris</italic> was inhibited by both the EO and EO-loaded NLC with concentrations between 0.281 and 0.563 mg/mL. The highest anti-<italic toggle="yes">Candida</italic> activity was achieved with the NLC containing higher SDS concentrations in the composition. No toxicity was observed at the MIC concentration. </td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B64-pharmaceutics-17-00178" ref-type="bibr">64</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NLC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Miglyol<sup>&#x000ae;</sup>812, Kolliphor<sup>&#x000ae;</sup> HS 15, NaCl, soybean lethicin, and eucalyptus EO (35% <italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>) or orange EO (40% <italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Eucalyptus and orange</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;165.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 &#x000b0;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">180</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Candida </italic>
<break/>
<italic toggle="yes">albicans</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro antimycotic activity.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Excellent antifungal activity by NLC loading both EO.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B65-pharmaceutics-17-00178" ref-type="bibr">65</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">LNP</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">System Composition</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">EO Loaded</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">EE (%)</td><td colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Stability Data</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Target</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Biological Tests</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Results</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reference</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Size (nm)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Storage <break/>Temperature</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Storage Time (days)</td></tr><tr><td colspan="11" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Human Applications</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NLC</td><td align="center" valign="middle" rowspan="1" colspan="1">Precirol<sup>&#x000ae;</sup>, oleic acid, poloxamer<sup>&#x000ae;</sup> 188 or cetyltrimethylammonium bromide, and <italic toggle="yes">Lippia sidoides</italic> EO (3% <italic toggle="yes">w</italic>/<italic toggle="yes">w</italic>) or <italic toggle="yes">Syzygium aromaticum</italic> EO (3% <italic toggle="yes">w</italic>/<italic toggle="yes">w</italic>)</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Lippia sidoides</italic> and <break/><italic toggle="yes">Syzygium</italic><break/><italic toggle="yes">aromaticum</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">84.6&#x02013;100.0 </td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;161.0 </td><td align="center" valign="middle" rowspan="1" colspan="1">25 &#x000b0;C, with thermal stress at 37 &#x000b0;C and 5 &#x000b0;C</td><td align="center" valign="middle" rowspan="1" colspan="1">28</td><td align="center" valign="middle" rowspan="1" colspan="1">SARS-CoV-2</td><td align="center" valign="middle" rowspan="1" colspan="1">Virucidal activity against SARS-CoV-2.</td><td align="center" valign="middle" rowspan="1" colspan="1">NLC that contained a quaternary ammonium surfactant and a mixture of <italic toggle="yes">L. sidoides</italic> EO and <italic toggle="yes">S. aromaticum</italic> EO (1:1) showed enhanced virucidal activity compared with formulations that contained a pure EO.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B90-pharmaceutics-17-00178" ref-type="bibr">90</xref>]</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">NE</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Tween<sup>&#x000ae;</sup> 80 and clove EO</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Syzygium aromaticum</italic>
</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">32.67</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">25 &#x000b0;C</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">40</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1"><italic toggle="yes">B. cereus</italic>, <italic toggle="yes">S. aureus</italic>, <italic toggle="yes">E. coli</italic>, <italic toggle="yes">K. oxytoca</italic>, <italic toggle="yes">C. albicans</italic>, <italic toggle="yes">C. neoformans</italic>, <italic toggle="yes">A. brasiliensis</italic>, <italic toggle="yes">A. flavus</italic> and <italic toggle="yes">A. fumigatus</italic></td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">In vitro antibacterial activity (MIC and antibiofilm activity study) and antifungal activity (MIC and MFC).</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">NE showed antibiofilm and antifungal activity significantly higher than control. NE exhibited MIC values against <italic toggle="yes">B. cereus</italic>, <italic toggle="yes">S. aureus</italic>, <italic toggle="yes">E. coli</italic> and <italic toggle="yes">K. oxytoca</italic> that ranged from 0.31 to 5 mg/mL and MBC between 0.62 and 10 mg/mL. For fungus strains, the MICs ranged from 0.78 to 12.5 mg/mL and the MFCs from 1.56 to 12.5 mg/mL.</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">[<xref rid="B91-pharmaceutics-17-00178" ref-type="bibr">91</xref>]</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">LUV</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Lecithin, cholesterol, dichloromethane/methanol and <italic toggle="yes">Zhumeria majdae</italic> EO</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Zhumeria majdae</italic>
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">92.3</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">118.0</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">4&#x000b0; C</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">A. baumannii</italic>, <italic toggle="yes">P. aeruginosa</italic>, <italic toggle="yes">S. typhimurium</italic>, <italic toggle="yes">K. pneumoniae</italic>, <italic toggle="yes">S. aureus</italic>, <italic toggle="yes">E. faecalis</italic>, <italic toggle="yes">E. coli, S. bovis</italic></td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Anti-biofilm activity, anti-quorum sensing activity, disk diffusion method, MIC, MBC, antioxidant activity and cytotoxicity study.</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">LUV had better antioxidant, anti-quorum sensing, and anti-biofilm activities than the free EO, along with biocompatibility.</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B92-pharmaceutics-17-00178" ref-type="bibr">92</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">LNP</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">System Composition</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">EO Loaded</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">EE (%)</td><td colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Stability Data</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Target</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Biological Tests</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Results</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reference</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Size (nm)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Storage <break/>Temperature</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Storage Time (days)</td></tr><tr><td colspan="11" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Human Applications</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NLC hybrid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tween<sup>&#x000ae;</sup> 80, xanthan gum, Precirol<sup>&#x000ae;</sup> and <italic toggle="yes">Carum carvi</italic> EO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Carum carvi</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40.0&#x02013;250.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 &#x000b0;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Escherichia coli</italic>, <italic toggle="yes">Staphylococcus aureus</italic>, <italic toggle="yes">Staphylococcus epidermidis</italic> and <italic toggle="yes">Pseudomonas aeruginosa</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro antibacterial activity (disc diffusion, MIC and MBC) and infected wound-healing in vivo assay.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The results show better antibacterial activity of the EO-based NLC in comparison with pure EO. Topical application of the EO-NLC decreased the bacterial colonization, shortened the inflammatory phase and promoted the proliferative phase in mice cutaneous wounds.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B93-pharmaceutics-17-00178" ref-type="bibr">93</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LUV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Soybean lecithin, cholesterol, chloroform, EO, Tween<sup>&#x000ae;</sup> 80, phosphate-buffered saline solution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Origanum vulgare</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">79.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;111.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 &#x000b0;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Trichophyton rubrum</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro antifungal activity: mycelial growth test.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Encapsulation of the EO in nanoliposomes was effective at increasing the antifungal activity against <italic toggle="yes">T. rubrum</italic> strains.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B94-pharmaceutics-17-00178" ref-type="bibr">94</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LUV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lipoid S75, mixture of soybean phospholipids and EO.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Citrus limon</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~86.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">152.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 &#x000b0;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">E. coli</italic>, <italic toggle="yes">P. aeruginosa</italic>, <italic toggle="yes">S. aureus</italic> and <italic toggle="yes">Candida albicans</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro antimicrobial tests (agar diffusion method and micro-dilution method) and in vitro biocompatibility.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The antimicrobial activity of the LUV was confirmed against all pathogens tested, and they demonstrated high biocompatibility in human keratinocytes.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B95-pharmaceutics-17-00178" ref-type="bibr">95</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NLC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Miglyol&#x000ae;, Precirol&#x000ae;, Poloxamer and <italic toggle="yes">Mentha pulegium</italic> EO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Mentha</italic>
<break/>
<italic toggle="yes">pulegium</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40.0&#x02013;250.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 &#x000b0;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S. pneumoniae</italic>, <italic toggle="yes">S. epidermidis</italic>, <italic toggle="yes">S. aureus</italic>, <italic toggle="yes">P. aeruginosa</italic>, <italic toggle="yes">E. coli</italic>, <italic toggle="yes">L. monocytogenes</italic>, <italic toggle="yes">B. anthracis</italic> and <italic toggle="yes">S. typhimurium</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro antibacterial activity (MIC and MBC), wound-healing assay and histopathological analyses.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Topical application of the EO-NLC reduced bacterial count under in vitro and in vivo assays, which favored wound healing.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B96-pharmaceutics-17-00178" ref-type="bibr">96</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">LNP</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">System Composition</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">EO Loaded</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">EE (%)</td><td colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Stability Data</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Target</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Biological Tests</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Results</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reference</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Size (nm)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Storage <break/>Temperature</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Storage Time (days)</td></tr><tr><td colspan="11" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Human Applications</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hybrid NE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tween<sup>&#x000ae;</sup> 80, chitosan, sodium alginate and thyme EO (1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Thyme</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">70.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;100.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 &#x000b0;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">E. coli</italic> and <italic toggle="yes">S. aureus</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro antibacterial test and cytotoxicity test.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibacterial activity by limiting the growth of Gram-negative and Gram-positive bacteria and showed lower toxicity than the controls.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B97-pharmaceutics-17-00178" ref-type="bibr">97</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NLC gel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Miglyo<sup>&#x000ae;</sup> 812, Precirol<sup>&#x000ae;</sup>ATO 5, Poloxamer<sup>&#x000ae;</sup>, xanthan gum and <italic toggle="yes">Peppermint</italic> EO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Peppermint</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;250.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">E. coli</italic>, <italic toggle="yes">S. typhimurium</italic>, <italic toggle="yes">P. aeruginosa</italic>, <italic toggle="yes">S. aureus</italic>, <italic toggle="yes">S. epidermidis</italic>, <italic toggle="yes">B. antracis</italic>, <italic toggle="yes">S. pneumonie, L. monocytogenes</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro antibacterial activity (MIC and MBC) and in vivo infected wound healing in mice model.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibacterial activity against Gram-positive and Gram-negative bacteria. The healing process of the infected wound was accelerated, with a decreased bacterial count and edema score.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B98-pharmaceutics-17-00178" ref-type="bibr">98</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NLC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kolliphor<sup>&#x000ae;</sup> RH40, Labrafil<sup>&#x000ae;</sup>, Softisan<sup>&#x000ae;</sup> 100, Tween<sup>&#x000ae;</sup> 80, clotrimazole, and <italic toggle="yes">Lavandula</italic> EO or <italic toggle="yes">Rosmarinus</italic> EO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Lavandula</italic> and <italic toggle="yes">Rosmarinus</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;200.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 &#x000b0;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">180</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Candida</italic> sps.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro antifungal susceptibility test.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antifungal activities of both EO were retained when they were loaded into the NLC formulations, and the co-existence of clotrimazole and EO led to an improvement in the antifungal effect.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B99-pharmaceutics-17-00178" ref-type="bibr">99</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tween 80, sandalwood EO and Ultrez</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Santalum album</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;230.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 &#x000b0;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">120</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">B. subtilis</italic>, <italic toggle="yes">S. aureus</italic>, <italic toggle="yes">E. coli</italic> and <italic toggle="yes">P. aeruginosa</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro antibacterial activity (MIC, MBC, agar diffusion assay, trypan blue assay).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EO-based NE showed activity against all bacteria analyzed, with greater antibacterial effects against <italic toggle="yes">E. coli</italic>, <italic toggle="yes">S. aureus</italic> and <italic toggle="yes">P. aeruginosa.</italic> These NE were stable for 2 months.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B100-pharmaceutics-17-00178" ref-type="bibr">100</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">LNP</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">System Composition</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">EO Loaded</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">EE (%)</td><td colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Stability Data</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Target</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Biological Tests</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Results</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reference</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Size (nm)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Storage<break/> Temperature</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Storage Time (days)</td></tr><tr><td colspan="11" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Animal Applications</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NLC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cocoa butter, beeswax, murumuru butter, poloxamer&#x000ae; solution and EO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Geranium, lemongrass, clove, cinnamon and oregano</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">151.8&#x02013;245.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 &#x000b0;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">210</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Campylobacter spp</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MIC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">They were able to inhibit bacterial growth at a low concentration (0.2 mg/mL).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B19-pharmaceutics-17-00178" ref-type="bibr">19</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NLC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spam 80, clove EO with &#x003b1;-mangostine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clove</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;200.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 &#x000b0;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">E. coli</italic>, <italic toggle="yes">Salmonella</italic> spp. and <italic toggle="yes">Klebsiella pneumoniae</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Penetration tests on gingival epithelial tissue.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The NLC had better penetration into the gingival epithelium, in addition to inhibiting the bacterial growth in the oral cavities of dogs.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B33-pharmaceutics-17-00178" ref-type="bibr">33</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LUV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oregano, cinnamon and clove EO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oregano, clove and cinnamon</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Clostridium</italic>, <italic toggle="yes">Escherichia</italic> and <italic toggle="yes">Enterobacteriaceae</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Real-time PCR. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A decrease in intestinal bacterial populations was observed when broiler diets were supplemented with 300 and 400 mg/kg of LUV.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B72-pharmaceutics-17-00178" ref-type="bibr">72</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">M. alternifolia</italic> EO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">M. alternifolia</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;200.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Pythium insidosum</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MIC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">There was positive antifungal activity, with the capacity to inhibit around 90% of the growth.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B73-pharmaceutics-17-00178" ref-type="bibr">73</xref>]</td></tr><tr><td colspan="11" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Agricultural Applications</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NLC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stearic acid and green tea</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fennel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">277.0&#x02013;287.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Cullex pipiens</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adulticidal/larvicidal assays.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The results show the nanosystem&#x02019;s potential larvicidal and adulticidal activity.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B8-pharmaceutics-17-00178" ref-type="bibr">8</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NLC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Carnauba wax, Tween&#x000ae; 80 and Mygliol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rosemary and thyme</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">288.1 and 347.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">M. persicae</italic>, <italic toggle="yes">T. urticae</italic> and <italic toggle="yes">F. occidentalis</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Assessment of contact toxicity on leaf discs.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The rosemary-EO-based NLC showed efficacy against all tested pests and the thyme EO-NLC, moderate insecticidal activity.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B34-pharmaceutics-17-00178" ref-type="bibr">34</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">LNP</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">System Composition</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">EO Loaded</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">EE (%)</td><td colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Stability Data</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Target</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Biological Tests</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Results</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reference</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Size (nm)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Storage<break/> Temperature</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Storage Time (days)</td></tr><tr><td colspan="11" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Agricultural Applications</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oleic acid, sodium glycocholate and polysorbate 20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Honeysuckle and patchouli</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">183.0&#x02013;250.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Cullex pipiens</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adulticidal/larvicidal assays.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The NLC-EO managed to reduce the larvae and had an adulticidal role, which was more effective than the respective EO.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B80-pharmaceutics-17-00178" ref-type="bibr">80</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sorbitan monooleate and polyoxyethylene sorbitan monooleate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Ayapana triplinervis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">88.3&#x02013;99.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Aedes aegypti</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Larvicidal/insecticidal assays.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The system increased the mortality rate.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B81-pharmaceutics-17-00178" ref-type="bibr">81</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polyethylene glycol and Tween&#x000ae; 80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Artemisia herba-alba</italic> and <italic toggle="yes">Melia azedarach</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;100.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Hyalomma dromedarii</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acaricidal assay.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Both EOs showed acaricidal activity in vivo.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B82-pharmaceutics-17-00178" ref-type="bibr">82</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tween&#x000ae; 80 and ethanol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Artemisia</italic> and <italic toggle="yes">Rosemary</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">199.0&#x02013;217.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Bemisia tabaci</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Entomotoxic and phytotoxic bioassays.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Artemisia-EO-based NE and rosemary-EO-based NE resulted in <italic toggle="yes">B. tabaci</italic> mortalities of 60% and 98%, respectively.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B84-pharmaceutics-17-00178" ref-type="bibr">84</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Saponin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pogostemon cablin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46.2&#x02013;71.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">54 &#x000b1; 1 &#x000b0;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Tetranychus urticae</italic> and larvae of <italic toggle="yes">Spodoptera litura</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Insecticidal assay.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NE formulations showed a high efficacy against <italic toggle="yes">T. urticae</italic> and antifeedant action against <italic toggle="yes">S. litura</italic> larvae.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B85-pharmaceutics-17-00178" ref-type="bibr">85</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tween 80, deionized water and ethanol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Moutan Cortex</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">150.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Dermatophagoides farinae</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fumigant, repellent and larvicidal assays.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EO-based NE showed good acaricidal activity at 48 h but poor fumigant effects against adult <italic toggle="yes">D. farinae</italic> at 12 and 24 h.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B86-pharmaceutics-17-00178" ref-type="bibr">86</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NIO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tween&#x000ae; 80 and soy lecithin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Azadirachta indica</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93.31</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4&#x02013;8 &#x000b0;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Xanthomonas</italic> and <italic toggle="yes">Pantoea</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro antimicrobial activity.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A significant increase in antimicrobial inhibition, with maximum inhibition at 10 mg/mL of EO-NIO.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B87-pharmaceutics-17-00178" ref-type="bibr">87</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">LNP</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">System Composition</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">EO Loaded</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">EE (%)</td><td colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Stability Data</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Target</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Biological Tests</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Results</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reference</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Size (nm)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Storage<break/> Temperature</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Storage Time (days)</td></tr><tr><td colspan="11" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Agricultural Applications</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tween&#x000ae; 20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ginger</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">73.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Xanthomonas oryzae</italic> pv. <italic toggle="yes">oryzae</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Disc diffusion method and glasshouse trial experiment.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The NEs efficacy was concentration dependent, where it reduced the bacterium growth in the rice plant leaf and suppressed the disease severity index.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B88-pharmaceutics-17-00178" ref-type="bibr">88</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NLC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Softisan<sup>&#x000ae;</sup> 100, Kolliphor<sup>&#x000ae;</sup> RH40 and Labrafil<sup>&#x000ae;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rosemary, lavender and peppermint</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;200.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Aphis gossypii</italic>, <italic toggle="yes">Spodoptera littoralis</italic> and <italic toggle="yes">Tuta absoluta</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antifeedant assay.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The rosemary-EO-based NLC was the most promisor system, where it exhibited excellent stability.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B89-pharmaceutics-17-00178" ref-type="bibr">89</xref>]</td></tr></tbody></table></table-wrap></floats-group></article>